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ABSTRACT 
 
STRUCTURE BASED LIGAND DESIGN FOR MONOAMINE TRANSPORTERS 
AND MITOGEN ACTIVATED KINASE 5 
 
 
 
By 
Sankar Manepalli 
May 2012 
 
Dissertation supervised by Jeffry D. Madura  
 Depression is a major psychological disorder that affects a person's mental and 
physical abilities. The National Institute of Mental Health (NIMH) classified it as a 
serious medical illness. It causes huge economic, as well as financial impact on the people, 
and it is also becoming a major public health issue. Antidepressant drugs are prescribed to 
mitigate the suffering caused by this disorder. Different generations of antidepressants 
have been developed with dissimilar mechanisms of action. According to the Center for 
Disease Control, the usage of antidepressants has skyrocketed by 400 percent increase 
over 2005- 2008 survey period. This dramatic rise in usage indicates that these are the 
most prescribed drugs in the US. Even with the FDA mandated “black box” warning of 
increased suicidal thoughts upon use of selected antidepressants, these drugs are still being 
used at a higher rate. 
 v 
 All classes of antidepressants are plagued by side effects with mainly sexual 
dysfunction common among them. To avoid the adverse effects, an emphasis is to 
discover novel structural drug scaffolds that can be further developed as a new generation 
of antidepressants. The importance of this research is to discover structurally novel 
antidepressants by performing in silico virtual screening (VS) of chemical databases using 
the serotonin transporter (SERT). In the absence of a SERT crystal structure, a homology 
model was developed. The homology model was utilized to develop the first structure-
based pharmacophore for the extracellular facing secondary ligand binding pocket. The 
pharmacophore captured the necessary drug-SERT interaction pattern for SERT inhibitory 
action. This pharmacophore was employed as one of the filters for VS of candidate 
ligands. The ten compounds identified were purchased and tested pharmacologically.  Out 
of the ten hits, three structurally novel ligands were identified as lead compounds. Two of 
these compounds exhibited selectivity towards SERT; the remaining lead compound was 
selective towards the dopamine transporter and displayed cocaine inhibition. The two 
SERT selective compounds will provide new opportunities in the development of novel 
therapeutics to treat depression. 
 For dopamine transporter (DAT), the study was based on recently developed 
structurally diverse photo probes. In an effort to better understand the binding profile 
similarities among these different scaffolds, the photo probes were docked into DAT. The 
finger print analysis of the interaction pattern of docked poses was performed to identify 
the inhibitor-binding sites.   
 For mitogen activated protein kinase 5 (MEK5), given the lack of structural 
information, a homology model of MEK5 was developed to guide the rational design of 
 vi 
inhibitors. Docking of known MEK5 inhibitors into the homology model was performed 
to understand the inhibitory interaction profile. Several series of analogues were designed 
utilizing the generated interaction profile.  
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Chapter 1. 
MONOAMINE TRANSPORTER STRUCTURE, FUNCTION 
AND DRUG DISCOVERY: A COMPUTATIONAL REVIEW 
1.1 Introduction 
Monoamine transporters (MATs) are important proteins that maintain 
neurotransmitter homeostasis in brain synapses.  The monoamine hypothesis shows that 
dysfunction of these critical gatekeepers result in the imbalance of monoamine 
neurotransmitters in the synapse, linked to various disease states such as depression, 
addiction and other major neurological disorders.
1-6
  The control of several body 
functions such as hunger, sleep and mood is maintained by neurotransmitter homeostasis.  
A critical understanding of MATs will help design and develop better drugs to treat 
disorders linked to MATs.
7
 
 
MATs are membrane proteins that span across the cell membrane lipid bilayer 12 
times; the polypeptide N- and C- terminals are in the cytoplasm (Figure 1.1).  
Experimental studies such as scanning cysteine accessibility mutagenesis (SCAM) were 
carried out on these proteins to elucidate the mechanistic details of substrate translocation 
and ligand binding.  Computational efforts were performed to understand the atomistic 
details of these proteins. Briefly, these studies can be divided as “pre-LeuT and post-
LeuT” and are described below.  Leucine transporter (LeuT), a bacterial transporter 
homologous to MATs, was crystallized in 2005.
8
 Proteins evolutionarily distant from the 
neurotransmitter sodium symporter family (NSS) were also used as templates to build the 
  2 
homology models of MATs, but were later found to be poor tools as the homology was 
very weak.
8
  Pre-LeuT based MAT efforts were ligand-based and included QSAR 
studies, ligand-based pharmacophores that were used in virtual screening (VS) efforts to 
identify novel compounds. 
As of now, LeuT is recognized as the closest relative to these MATs, and is 
shown to have an inverted symmetry between the two domains that are formed by six 
transmembrane helices each. Only two conformations of the leucine substrate 
translocation cycle (Figure 1.2), one with open-to out and the other being ligand bound 
(occluded) were crystallized. The inward-facing conformation is the critical missing 
piece of the puzzle.  
A clear understanding of the MATs conformational transitions during the 
substrate translocation will help in the design of better drugs.  Different MAT homology 
models were constructed using the two available conformations of LeuT. The homology 
models were employed in various studies to discern the mechanism of action of various 
MAT inhibitors that led to opposing conclusions.
9, 10
 There is a dearth of structural 
diversity in the MAT inhibitor ligands, and no studies were performed to identify novel 
ligands with increased potency and reduced side effect profile. Recent structure-based 
efforts have identified diverse novel compounds (hits) that can be optimized further as 
leads (inhibitors) that bind to MATs.
11-13
 
The following is a review of the computational efforts of MAT homology model 
construction, their use in understanding MAT dynamics, substrate translocation, inhibitor 
binding and especially the identification of novel scaffolds through virtual screening. 
 
  3 
 
 
 
 
Figure 1.1. MATs embedded in lipid bilayer. hSERT (green helices) is embedded 
within a POPE lipid bilayer (Van der Waals spheres) with both polypeptide terminals 
within the intracellular space.  Lipophilic tails (gray) of the phospholipids are oriented 
toward the center of the cell membrane, arranged tail-to-tail; the polar head groups 
containing phosphorous (pink), oxygen (red) and nitrogen (blue) atoms are oriented 
toward the hydrophilic borders of the membrane.  The S1 (yellow) and S2 (cyan) 
substrate binding pockets are displayed as surfaces.   
 
 
 
 
 
 
 
Extracellular 
Intracellular 
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Figure 1.2. The three minimally required conformations of substrate translocation 
cycle. TMs 1,3,6,8 that form the substrate translocation pore are presented as bars. The 
outward facing conformation opened towards extracellular space allows the entry of 
substrate (S) and ions (Na
+
) into the protein to form the occluded conformation. The 
inward facing conformational transition is achieved with the release of substrate and ions 
into the cytoplasm.  
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1.2 Generation of MAT Homology Models 
1.2.1 Pre LeuT  
 Despite the lack of a closely related protein crystal structure, MAT homology 
models were attempted as early as 1994, without the use of a structural template.  A DAT 
model was generated using the combination of 1) multiple sequence alignment (MSA) of 
10 neurotransmitter sodium symporter (NSS) transporter cDNAs (hDAT, hNET, hSERT, 
hGABA, rGABA, rGLY, rTAU, rCHO, rSERT and dog betaine) and 2) hydropathy plots 
to assign TM domain length.
14
  The DAT homology model was used to discuss the 
mechanism for substrate/ion binding and cocaine inhibition of the dopamine uptake.
14
  A 
template-independent SERT homology model also employed MSA and hydropathy plots, 
using online servers- PHD Predict Protein,
15
 DAS,
16
 TMpred and TopPred2.
17
  A cocaine 
binding pocket was created in SERT with five TM helices using the data from ligand 
binding and site-directed MAT mutagenesis.
18
  The remaining seven TM domains were 
positioned and refined by electrostatic calculations using the electrostatics program 
GRASP.  Follow up docking studies with this SERT model suggested that citalopram and 
cocaine interact with the charged side chain of D98 (TM1), while the TCA imipramine 
bind elsewhere.
18
 The TM domain juxtapositions in the generated homology models were 
largely speculative and not particularly accurate, owing to the lack of a template of 12 
TM domain transporters.  
 The first template-based MAT models were constructed using the 12 TM 
facilitated diffusion transporter with sequence identity 13% or less.  MAT models were 
derived from the mutational data of two such E. coli proteins, the Na
+
/H
+ 
antiporter 
  6 
(NhaA) and the lactose permease (LacY), with the NhaA electron density projection map 
serving as a template.
19
  The resultant MAT models were used to localize citalopram and 
cocaine binding as well as the identification of substrate permeation pathway.
20-22
  It was 
proposed that Y95 (TM1) of SERT to be responsible for the selectivity of the S-
enantiomer of citalopram (Celexa
TM
); the analogous residue was implicated in DAT 
binding of cocaine and its analogs.
21
  A final round of non LeuT-based MAT homology 
models employed an inward- (cytoplasm-) facing LacY crystal structure as a template.
23
 
The LacY, best characterized of all membrane transporters, is a 12 TM protein with six 
TM helices in each domain.
24
  Upon creating an inward-facing SERT model, an outward-
facing conformation was generated through a rigid body rotation of ~60° of both the 
domains.  The SERT conformation thus generated was later used to build the outward-
facing DAT and NET models. The MAT models thus developed were utilized to dock 
cocaine, amphetamine and citalopram to identify the potential inhibitor binding sites.
25
  
Unfortunately, the X-ray structures of NhaA and LacY were later found not to 
appreciably resemble that of a true MAT homolog, the bacterial leucine transporter LeuT. 
 
1.2.2 Post LeuT (2005 - present) 
 The publication of a crystal structure (pdb id: 2a65) of the leucine transporter 
(LeuT) from Aquifex aeolicus,
8
 a thermophilic bacterium, provided the first reliable MAT 
template for computational studies as it is the closest prokaryotic orthologue to the NSS 
family.
26, 27
  The LeuT crystal structure launched a wave of new MAT models that 
continue to be corroborated by biophysical studies.  Several additional LeuT crystal 
  7 
structures with inhibitors bound were also crystallized.
28-31
 Unless otherwise specified, 
the models discussed herein were based on the first available LeuT crystal structure (pdb 
id: 2a65).  
 
1.2.2.1 Dopamine Transporter (DAT) 
Several DAT models were constructed using the LeuT as a template (Table 1.1), 
but the first LeuT-based DAT model was reported by Huang et al. in a study of dopamine 
interaction with the transporter and the substrate permeation pathway.
32
  Binding free 
energy calculations on the proposed binding mode of dopamine in DAT were in close 
agreement to the experimental free energy observed in this study.
32
  Additional molecular 
dynamic (MD) studies with this DAT model suggest that cocaine initially binds to a site 
that is distinct from that of the dopamine binding site.
33
   In stark contrast, Beuming et al. 
used a DAT model and a new multiple sequence alignment (MSA) to suggest that 
cocaine, benztropine, and amphetamine bind in the primary substrate site also referred to 
as S1.
34
 Mutagenesis and intramolecular cross-linking studies performed on DAT also 
supported this proposal.
35
  
Following this, a study by Indarte et al. elaborated the dopamine binding in DAT 
indicating the likelihood of a primary and a secondary substrate site known as S2. This is 
the first report that indicated the presence of two distinct binding sites (Figure 1.3)
10
. The 
same study docked dopamine and d-amphetamine into three different rDAT models, and 
from the results it was evident that in addition to the primary binding site, a secondary 
extracellular pocket exists. It was proposed as the secondary substrate site that acts as a 
temporary staging area for substrate translocation and a potential site for inhibitors.
10
 
  8 
Xhaard et al. proposed an alternate binding mode for substrates by docking 
dopamine, norepinephrine and serotonin into the S1 site of DAT, NET and SERT 
homology models respectively.  Additionally, the study proposed that the aromatic 
hydroxyl substituent chelates with the Na1 in the pocket known as the “chelation mode” 
as opposed to an interaction between the amine nitrogen and the Na1 in the “ionic 
mode”.36 
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Figure 1.3. Ligand-accessible regions of MATs (SERT). Pocket space available to the 
ligands in the deeper S1 (yellow) and the extracellular S2 (cyan) pockets are displayed as 
surfaces. Selected residues that define each pocket are displayed as sticks (atomtype 
color). For clarity, only the main TM contributors to SERT ligand binding pockets are 
highlighted: TM 1 (pink), TM 3 (green), TM 6 (gold), TM 8 (brown) and EL 4 (blue). 
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A number of MAT homology models were constructed using Beuming sequence 
alignment.
34
 The alignment was generated using 344 NSS family proteins, and most of 
the studies utilized models based on this comprehensive alignment (Figure 1.4). 
Guptaroy et al. used a DAT model to study the local conformational changes associated 
with a T62D mutation. The highly conserved T62 residue is located in the N-terminal 
region, and the mutation of T62 favored the inward-facing conformation of DAT 
suggesting a substantial role in the substrate translocation cycle.
37
 
 Schmitt et al. generated a DAT model based on the desipramine-bound LeuT 
crystal structure (pdb id: 2qju) to study the interaction profile of bivalent 
phenethylamines.
38
 The docking studies suggested that the long flexible phenethylamines 
span the substrate translocation pore of the protein, simultaneously occupying the S1 and 
S2 pockets.  The W84L and D313N DAT mutants also suggested that phenethylamines 
prefer inward-facing DAT conformation, and further concluded the presence of multiple 
low-affinity substrate sites throughout the translocation pore.
38
   
In a study focused on MAT-inhibitor interactions, the electrostatic potential 
surface for DAT was calculated, by docking cocaine and clomipramine into S1 and S2 
sites respectively.
39
 In a recent study by Hong et al. four residues were identified for 
SCAM studies, which led to the conclusion that DAT prefers the outward-facing 
conformation in a cholesterol-rich lipid environment.
40
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Figure 1.4. Sequence alignment of hDAT, hNET, and hSERT amino acid sequences 
aligned to LeuT following Beuming alignment.  Residue position in the chain is 
indicated with numbers (red) before and after each row.  Predicted TM regions are 
indicated above each sequence row.  Identical (blue) or similar (yellow) residues across 
all sequences are highlighted.  Gaps between sequences are exhibited with dots.  
Residues forming the extracellular charged gate (blue spheres), extracellular hydrophobic 
gate (red stars) and the cytoplasmic charged gate are indicated below the sequence rows. 
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Author Year Template 
(PDB ID) 
Sequence 
Alignment 
Sequence 
Identity 
(%) 
Software  
Edvardsen 1994 None Developed - MIDAS 
Ravna 2003 NhaA Developed 7 MIDAS plus 
Ravna 2006 LacY 
(1pv6) 
Developed 5 ICM 
Huang 2007 LeuT Developed 20.4 Insight II 
Indarte 2008 LeuT 
 
Developed - MOE, Robetta  
3D-JIGSAW  
Xhaard 2008 LeuT 
 
Developed - Malign, 
MODELLER 
Beuming 2008 
 
LeuT 
 
Beuming 
 
20 MODELLER 
Guptaroy 2008 LeuT 
 
Beuming 20 MODELLER 
Ravna 2009 LeuT Beuming 20 ICM 
Schmitt 2010 LeuT 
(2qju) 
Beuming 20 MODELLER, 
MOE 
Hong 2011 LeuT Developed - Swiss-Pdb 
Viewer 
 
(-) information not provided 
Table 1.1. Construction of DAT homology models in chronological order. 
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1.2.2.2 Serotonin Transporter (SERT) 
Of the three MATs, most of the computational focus was on SERT, and so 
numerous homology models were constructed (Table 1.2).  Ravna et al. reported the 
construction of first SERT model, which was used to identify amino acid residues 
involved in ligand binding.
41
  Using the ICM pocket finder, a pocket formed by TM 1, 3, 
6, and 8 that corresponds to the leucine binding site in LeuT was identified.
41
  
Subsequently, a similar conclusion was reached by a study in which LeuT and SERT 
substrate binding sites were compared.
42
  Additionally, the study suggested that the larger 
serotonin substrate may be accommodated in a large pocket with smaller side chains, and 
proposed the importance of D98 (TM1) in SERT for substrate interaction.
42
  
  To further their understanding of the previously reported SCAM data,
43
 both 
Zhang et al. and Rudnick et al. utilized a SERT model to propose that the residues in 
TM5 may be involved in substrate permeation pathway.
44
  In a similar SCAM study, the 
role of TM7 was also examined by correlating computational insights with the SCAM 
data.
45
  Through these studies, it was proposed that TM7 was involved in ion dependence 
and translocation pathway, possibly through the rotation of TM7.
45
  With a similar 
rationale, a SERT homology model was used to support the results from Zn
+2
 binding 
experiments, wherein the data suggested that residues in TM1 and TM3 were in close 
proximity and oriented towards each other, especially V102 and I179.
46
  To determine the 
importance of the N-terminus in amphetamine action, a SERT homology model was 
developed by Sucic et al. The study concluded that the N-terminus was involved in 
substrate efflux by acting as a lever that reverses the substrate transport in the presence of 
amphetamine.
47
 
  14 
A SERT homology model was generated and used by Jorgensen et al. to identify 
the potential binding site of escitalopram by docking. The study concluded that the 
binding mode observed was well in agreement with the already available mutagenesis 
data.
48
 In a study focused on buspirone binding at SERT, two hSERT models were 
constructed based on the inward-facing LacY (pdb id: 1pv6) and the outward-facing 
LeuT.
49
  Various buspirone analogs were then docked into both the SERT models to 
ascertain the residues involved in binding. The two distinctive models illustrated the 
differences in the binding pocket environment created by different conformational states.  
Specifically, in the LeuT-based SERT model, two binding sites were identified 
corresponding to high- and low-affinity sites in LeuT.
49
  
 In an eloquent study, the paired mutant-ligand analogue complementation 
(PaMLAC) method was used to study the binding of serotonin in the SERT primary 
substrate pocket.
50
  In this study various serotonin analogs were docked into the final 
SERT model using an induced fit method. The docked poses were experimentally 
analyzed by coupling with mutational data generated from thirteen different single point 
mutants, which concluded that serotonin interacts with D98, A173 and T439 residues.
50
   
A more recent study on the substrate binding by Kaufmann et al. 
51
 suggested that 5-HT 
binds in a different orientation, similar to the one proposed by Jorgensen et al.
48
   
Kauffman et al. built human and drosophila SERT models to identify the 
differences conferring species selectivity.  Different 5-HT analogs were docked; and the 
most favorable pose oriented 5-HT in a “down” binding mode. The indole nitrogen is 
located near Y176/Y171 residue pointing toward the interface between TM3 and TM8. 
This was well in agreement with SCAM and mutagenesis data.
51
 A SERT model was 
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utilized to examine the substrate binding, where several 5-HT analogs were docked into 
S1 site, and molecular dynamics was performed on the selected protein-ligand 
complexes. The study concluded that IL1 and TMs 6, and 8 play an important role in the 
substrate translocation.
52
 
 Binding of TCAs to the SERT was studied by using a model constructed using 
open-to-out conformation of LeuT (pdb id: 3f3a).
28
  Analysis of the docked poses showed 
protein-ligand interactions that were in agreement with site-directed mutagenesis data, 
suggesting the presence of a vestibular low-affinity binding site for TCAs. The tricyclic 
ring of the TCAs occupied the S2 vestibular pocket, while the amine tail probed into S1 
site in the generated poses.
53
 Using both the open-to-out LeuT (pdb id: 3f3a) and the 
occluded conformation (pdb id: 2a65), different SERT models were developed to study 
inhibitor binding.  The high affinity S-enantiomer of citalopram (escitalopram) was 
docked into SERT S1 site, and 64-point mutations were created to experimentally 
analyze the docked poses. Docking into S2 was not considered in this study because 
previous mutational studies for nonconserved residues in this region did not produce a 
significant biological effect.
54
  Andersen et al. proposed two new residues, N177 and 
F341, in S1 to be critical for the escitalopram binding.
55
  
 Most recently, Manepalli et al. utilized a SERT model as a tool for drug 
discovery.
13
  In this study SERT models were developed based on four different 
alignments: Yamashita, Beuming, Celik, and the Manepalli alignment, a modified Celik 
alignment.  The Manepalli alignment based model was used later for in silico virtual 
screening (VS) of a subset of ZINC database to identify novel chemotypes.  Furthermore 
the use of this model in optimizing a previously identified hit was also reported 
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recently.
12
 Herein, docking and flexible alignment studies were used to guide the 
chemical transformation of a non-selective MAT inhibitor into a SSRI.
12
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      (-) information not provided. 
   Table 1.2. Construction of SERT homology models in chronological order.   
 
 
 
Author Year Template 
(PDB ID) 
Sequence 
Alignment 
Sequence 
Identity 
(%) 
Software 
Ravna 2001 - Developed - PHD, WHATIF 
Ravna 2003 DAT Developed 80 ICM 
Ravna 2006 NhaA Developed 7 ICM 
Ravna 2006 LacY 
(1pv6) 
Developed 5 ICM 
Ravna 2006 LeuT Developed 20 ICM 
Zhang 2006 LeuT Beuming 20 - 
Henry 2006 LeuT Yamashita 20.5 SCWRL 
White 2006 LeuT Yamashita 20.5 - 
Jørgensen  2007 LeuT Developed - MODELER 
Forrest 2007 LeuT Beuming 20 NEST 
Xhaard 2008 LeuT Developed - Malign 
Jarończyk 2008 LacY 
(1pv6) 
LeuT 
(2a65) 
Developed - ICM, Bioedit 
Celik 2008 LeuT Developed 22.9 MODELER 
Kaufmann 2009 LeuT Beuming 17 ROSETTA 
suite 
Ravna 2009 LeuT Beuming 20 ICM 
Sarker 2010 LeuT 
(3f3a) 
Beuming 20 MODELLER 
Andersen 2010 LeuT 
(3f3a) 
Beuming 20 MODELLER 
Wenthur 2010 LeuT Beuming 20 MODELLER 
Sucic 2010 LeuT Beuming 20 MOE 2007.08 
Gabrielsen 2011 LeuT Beuming 20 ICM 
Manepalli 2011 LeuT Developed 23.9 DS 2.5.1 
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1.2.2.3 Norepinephrine Transporter (NET) 
 In the past, NET was not given enough attention as compared to DAT and SERT, 
however with the promising results of norepinephrine reuptake inhibitors (NRIs) and 
dual-acting norepinephrine-dopamine reuptake inhibitors (NDRIs), attention to NET is on 
the rise (Table 1.3). Aside from the NET models built by Ravna et al. along with SERT 
and DAT models, few attempts have been reported.
22, 25, 56-58
 A NET homology model 
was generated to visually examine the effects of mutations on the binding of TCA 
desipramine and conopeptide χ-MrIA, a noncompetitive, selective NET inhibitor.56  
Several residues presumed to be important for χ-MrIA interactions were located near the 
extracellular pocket of the transporter. Correlating the mutagenesis data along with 
docking studies, it was concluded that the binding sites of the conotoxin and TCA 
overlap while the conotoxin and norepinephrine sites are discrete.
56
   
In a similar unpublished study by Nolan et al. two distinct binding pockets were 
identified using a NET model based on the open-to-out LeuT crystal structure (pdb id: 
3F3A).  Adaptive Poisson-Boltzmann Solver (APBS) calculations of docked poses for 
known NET ligands were compared to experimental data, which concluded that a 
secondary site exists in the vestibular region of NET where inhibitors bind, particularly 
the TCAs.  In a study on NET ligand binding, Hill et al. used previously built DAT model 
32, 33
 as a template to construct a NET model, as there is a high similarity (67%) between 
DAT and NET.
57
  NE was docked into the S1 site and MD simulations were carried out 
on the resulting NET-NE complex to examine the influence of cocaine and its analogs, 
RTI-33 and RTI-113, on substrate binding.  The study concluded that cocaine occupies a 
pocket far removed from the S1 substrate site.
57
 A recent effort to identify the 
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determinants conferring inhibitor selectivity for SERT and NET was performed.
58
 Herein, 
the structural details of SERT/NET selectivity were studied for citalopram and talopram, 
an SSRI and NRI respectively.  Mutational data from this study suggested that the 
binding pocket of SSRIs overlap the S1 pocket whereas talopram binds at a distinct site.
58
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 (-) information not provided 
Table 1.3. Construction of NET homology models in chronological order. 
 
 
 
 
 
 
 
 
 
Author Year Template  
(PDB ID) 
Sequence 
alignment 
Sequence 
Identity (%) 
Software 
Ravna 2006 NhaA Developed 7 ICM 
Ravna 2006 LacY Developed 5 ICM 
Paczkowski 2007 LeuT 
 
Beuming 20 MODELLER 
Hill 2011 DAT Beuming 66 Insight II 
Andersen 2011 LeuT Beuming 20 - 
Nolan 
(unpublished) 
2011 LeuT 
(3f3a) 
Beuming 20 DS 2.5.1, 
APBS 
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1.3 Molecular Dynamics (MD) on MATs 
1.3.1 DAT Dynamics 
Of the three MATs, DAT and SERT were the most studied, which may be due to 
their involvement in several disease states. Molecular dynamics simulations were 
performed on DAT models even before LeuT was crystallized. Edvardsen et al. 
calculated the interaction energies of DAT complexes with the substrate dopamine and 
two enantiomers of the psychostimulant cocaine.
14
 Another study performed by Ravna et 
al. later concluded that changes in TM helical arrangement constricted the translocation 
pathway suggesting tropane analogues cannot fit in the putative ligand pocket.
20
  
The first full-fledged MD study on DAT models constructed using LeuT was 
performed by Huang et al.
32
  Molecular dynamics on both apo DAT and DAT- dopamine 
complex were performed to localize the substrate-entry pathway. The calculated strength 
of dopamine binding to DAT evaluated by molecular mechanic/Poisson-Boltzmann 
surface area (MM-PBSA) was -6.4 kcal/mol that was similar to the experimental binding 
energy (-7.4 kcal/mol).
32
 Following this study, several DAT complexes were generated 
by docking ligands like dopamine, amphetamine, cocaine and its analogues, benztropine 
and its analogues into DAT.
9
  Of the different complexes generated, the complexes of 
DAT-CFT (a cocaine analog) and DAT-DA were studied further using MD simulations. 
Using mutagenesis studies, intramolecular cross-linking studies, docking and molecular 
dynamics, it is proposed that cocaine and its higher affinity analog WIN-35,248 can go 
deeper into DAT and occupy S1 substrate pocket which was not shown previously.
35
  
The effect of mutation of a highly conserved T62 residue in the N-terminal of 
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hDAT in the [RETW] motif on dopamine uptake was studied using free energy 
perturbation (FEP) and mutational studies. The study concluded that T62 holds DAT in 
an open to outward conformation towards the extracellular space favoring dopamine 
uptake.
37
 Huang et al. extended their previous MD studies
32
 on DAT to explain the 
mechanism of cocaine inhibition on dopamine uptake.
33
 The study concluded that 
dopamine and cocaine bind at discrete non overlapping pockets and cocaine decreases the 
kinetic turnover of DAT by binding in the extracellular pocket.
33
 The conclusion of this 
study directly contradicted the study performed by Beuming et al. which proposed a 
single overlapping binding site for cocaine and dopamine.
9
  
 Gedeon et al. performed dynamics on DAT homology model constructed using 
LeuT. The study concluded that the extracellular salt bridge R85 (TM1) – D476 (TM10) 
is formed less frequently in the presence of a substrate at S2.
59
  Biased steered molecular 
dynamics was performed by applying a force to dopamine and pulled in both the 
extracellular and intracellular ways to identify the whole permeation pathway.
60
 A 
stopover site towards extracellular space corresponding to S2 pocket was identified. The 
study was extended further by placing a second substrate molecule in the S1 pocket, 
which finally concluded that the presence of a second substrate molecule in the S2 site 
had an allosteric effect on the substrate in S1 pocket, causing it to get released into the 
cytoplasm.
60
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1.3.2 SERT Dynamics  
The first full-fledged dynamics on SERT employed complexes of the SERT-
serotonin and SERT-escitalopram generated using docking.
61
 It was shown that the 
extracellular hydrophobic gate residue Y176 would embrace different conformations to 
better accommodate the changes in the binding pocket.
61
  Following this study, dynamics 
was performed to verify whether the SERT model constructed using LacY would convert 
to SERT built using LeuT. It was noticed that there was no impact on the helical packing 
of SERT based on LacY, and did not resemble the SERT model constructed using 
LeuT.
49
 
MD studies on the models of wild type SERT, T81A and T81D mutants were 
performed to focus on how the N-terminus (Thr81) would influence the SERT 
conformation.
47
 It showed the incidence of intracellular structural changes resulting in the 
opening of intracellular vestibule. The same study also showed that the mutation of T81A 
would induce an inward facing conformation by increasing the distance between the 
terminals. This equilibrium shift towards increased SERT inward facing conformation 
favored the amphetamine-induced efflux of 5-HT. The equilibrium hypothesis was tested 
experimentally by the removal of first 64 residues at the N-terminus, and tethering of N-
terminal completely obliterated the amphetamine induced substrate efflux. The final 
conclusion of this study was the importance of the N-terminus, which induces 
conformational changes by acting as a lever.
47
  
 The trajectory analysis of molecular dynamics performed on SERT showed a 
substantial movement of TM7 especially, the M370 and S375 residues.
45
  SCAM studies 
were followed up to identify the residues that are exposed towards the hydrophilic 
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environment. The combined analysis of MD and SCAM suggest the importance of TM 7 
in addition to TMs 1, 3, 6 and 8. The same SERT homology model also identified 
residues, V366 and M370 exposed towards the lipid bilayer, thus reducing their 
accessibility towards the MTSEA reagents. Finally, they concluded that Na ion exodus 
rotates TM7 to expose V366 and M370 towards MTSEA reagents.
45
 
An effort to study the substrate translocation in SERT was launched recently.
52
 
Different SERT complexes of apo SERT, SERT-serotonin and SERT-escitalopram were 
generated and MD was performed. Careful analysis of the MD trajectories showed that 
SERT adopts different conformational changes that assist in the substrate translocation.
52
 
Koldsø et al. performed the longest MD simulations on SERT.
62
 The study identified that 
the outward facing single substrate-bound SERT complex transformed to an inward 
facing conformation thus strengthening the claim of the absence of allosteric effect. The 
doubly bound substrate complex in SERT did not show any signs of the substrate 
translocation; rather, the loosely bound substrate got dissociated towards extracellular 
pocket. The role of D437 residue in ion transport was shown along with the hydration of 
substrate and Na2 ion, which is the ion that gets released into the cytoplasm.
62
  
 
1.4 Ion (Na+, Cl-) Binding Sites 
Structure-based computational efforts were directed towards identifying the 
binding sites for two Na
+
 and one Cl
-
 ion, the essential components for monoamine 
transporter function (Figure 1.5). While residues interacting with two bound Na
+
 ions in 
LeuT crystal structures were conserved amongst the NSS proteins (Figure 1.6), little was 
known about the binding domain of the Cl
-
 ion, as it is not essential for many NSS 
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members including the LeuT, Tyt1 and TnaT.  With this, a SERT homology model was 
developed in an effort to elucidate the Cl- ion-binding site in MATs.
63
  The negatively 
charged residues in LeuT that may replace the role of Cl- ion in the MATs were 
identified using the Multi-Conformer Continuum Electrostatics (MCCE) method. It was 
identified that the E290 of LeuT was nonconserved among Cl
- 
dependent transporters, 
corresponding to a serine in the MATs (S372 in SERT).  The placement of a Cl
-
 ion at 
this position in the SERT model showed coordination between the hydroxyl and amine 
hydrogen’s of Y121, S336, N368, S372 and is in close proximity to Na1 (~5Å) 
suggesting that Cl
-
 at this position would stabilize the binding of Na1 ion. 
Experimentally, the S372 and N368 mutants displayed decreased function and moreover, 
the substitution of these residues with a negatively charged residue produced a Cl
-
 ion 
independent transporter with reduced activity.
63
 Similar experimental studies support 
these findings that likewise suggest that a Cl
-
 ion or a negatively charged residue is 
required for transport.
64, 65
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Figure 1.5. The top view of proposed ion binding sites in MATs (SERT). The 
residues of helices, TM1(yellow), TM2(blue), TM6(pink), TM7(brown) and TM8 (red) 
that interact with substrate(green sticks), sodium (orange) and chloride (green) ions are 
displayed as sticks. 
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Figure 1.6. The close-up view of the ion-binding sites in MAT (hSERT). Substrate 
(green sticks) Na
+
 ions (orange spheres) and Cl
- 
ions (green spheres) are displayed. The 
residues interacting with these ions are presented as sticks in atom type color and the 
corresponding residues in DAT (blue), NET (red) and SERT (green) are shown. 
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1.5 Virtual Screening 
 
In addition to homology models, ligand-based models were proven useful in the 
study of transporter interactions and ligand recognition. Prior to the availability of NSS 
crystal structures, computational approaches relied heavily on known MAT ligands and 
their associated structure-activity relationships (SAR). A few caveats exist with 3D 
ligand-based studies including the assumption that all training set compounds bind at the 
same site of the same protein in a similar conformation.  
1.5.1 Ligand-Based VS 
 
While most ligand-based models have served to define the necessary features 
common to known ligands, some of these models were applied in the search for potential 
new scaffolds through virtual (in silico) screening.  An early ligand-based virtual 
screening study on the DAT featured a pharmacophore model based on just two 
compounds, cocaine and WIN-35065-2.
66
  The model consisted of three features: a 
nitrogen atom, a carbonyl group and an aromatic ring. Screening of the National Cancer 
Institute (NCI) database afforded 4094 compounds from which 44 out of the 70 tested 
experimentally were proven to inhibit DAT at 10 μM.  The most potent of these hits 
exhibited an uptake inhibition potency of 274 nM, 155 nM, and 108 nM at DAT, SERT, 
and NET respectively.
66
  An analogue of the quinuclidine scaffold was identified as a 
novel DAT inhibitor in a different study.
67
  Following the analysis of known DAT 
ligands lacking a carbonyl atom, the pharmacophore model already proposed was refined 
to include two additional features- an aromatic group and a tertiary amine.
68
  Screening of 
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the Advanced Chemical Dictionary (ACD) database with the modified pharmacophore 
model resulted in the identification of eight hits with IC50 values less than 10 μM.68  
Applying slight modifications to the distance constraints between the nitrogen 
atom and two aromatic features, the model afforded indole class of compounds with a 
NET and SERT affinity of 137 nM and 126 nM respectively.
69
  In response to the report 
that a tertiary nitrogen in tropane analogs was unnecessary,
70
 Enyedy et al. refined 
existing model by substituting a hydrogen-bond acceptor to tertiary nitrogen. The refined 
model was used for screening the NCI database that resulted in 1104 hits. Experimental 
testing of these compounds identified two hits with DAT uptake inhibition potency of 2.3 
μM and 0.255 μM respectively.71  A similar pharmacophore was derived from mazindol 
that consists two lipophilic aromatic rings along with one nitrogen atom. The 
pharmacophore was used to screen the ACD database containing 225,000 compounds 
which identified three compounds with Ki values of 128 nM, 48 nM and 24 nM, 
respectively.
72
  
Using an undisclosed VS method, a potent NET-selective compound with an 
uptake inhibition potency of 1 nM was identified.
73
  A pharmacophore model for NET 
was generated by studying the conformations adopted by milnacipran in solution and 
used in the design of analogs with better pharmacological profiles at MATs.
74
 The 
generation of a pharmacophore model based on the NET-selective χ-conotoxin, a peptide 
component of marine cone snail venom resulted in the design of a compound which has 
entered phase II clinical trials.
75
   
In an effort to compare the necessary features for activity amongst MATs, 
different pharmacophore models were generated separately for each transporter using a 
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training set containing either tropane analogs or GBR-12909 like compounds. The study 
highlighted the similarities as well as differences in the potential binding modes by 
coupling structures with biological activity. It was suggested that minor modifications to 
a core scaffold can confer selectivity for one transporter over the others.
76
 A study was 
attempted to differentiate the pharmacophore features necessary for SERT and D2 
receptor binding among a series of dual-acting piperazine ligands. The SERT 
pharmacophore model consisted of basic nitrogen, a sterically restricted area around the 
nitrogen, an aromatic region, and a general hydrophobic region.
77
 While these 
pharmacophore features were the same as those of the D2 receptor, the three dimensional 
arrangement of features differed, suggesting the flexibility of dual ligands vital for 
adopting different conformations to bind these two proteins.
77
   
 
1.5.2 Structure-Based VS 
 
The utility of MAT homology models was not limited to mechanistic and binding 
studies.  Recent reports demonstrate the value of using these models for the identification 
of novel chemotypes.
11, 13
 To date there have been only two reports describing the 
discovery of novel MAT ligands through structure-based virtual screening wherein both 
have focused on the extracellular vestibular region (S2).
11, 13
  The first DAT-based VS 
approach used a structure-based S2 pharmacophore to screen a chemical database 
containing over 140,000 compounds. Ten final compounds were selected based on the 
score (Affinity dG in MOE), predicted pKi, and visual inspection to be 
pharmacologically tested for activity at the MATs.  MI-4, an ifenprodil analog, was 
discovered to have affinity at all three transporters.
11
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The first structure-based VS on SERT was approached more recently using a 
pharmacophore developed from S2 and halogen binding pockets (HBP).
13
 Herein, a 
subset of the ZINC database (~ 1 million compounds) was screened using high-
throughput docking in MOE. Visual inspection along with the Affinity dG score aided in 
the selection of hit compounds for pharmacological analysis. This study resulted in three 
structurally novel compounds, two selective SERT ligands (SM-10 and SM-11) and one 
DAT selective compound (SM-14) with no affinity towards the other transporters in both 
the cases.
13
 The SERT model was equally used to refine a hit compound (MI-17) 
identified through the DAT VS study to create a more selective SSRI (MI-17 hybrid).
12
 
The first NET-based VS effort employed S1 pocket to screen Kyoto Encyclopedia of 
Genes and Genomes (KEGG) drug database containing 6436 known drugs. Ten of the 
final eighteen hits showed micromolar affinity towards NET. The study was more like 
drug repurposing for already known molecules and not a pure VS approach to identify 
novel compounds. 
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Figure 1.7. Different approaches used in virtual screening to identify novel scaffolds. 
Ligand-based methods use models that employ different pharmacophore features labeled 
F1-F5 with a volume constraint to screen a small molecule library. Structure-based 
methods filter through virtual small molecule libraries to identify hits (orange spheres) by 
docking them into the binding pockets of MATs (green helices). Hybrid approaches use 
ligand-based VS followed by structure-based VS. 
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Name Structure Binding affinity (Ki (nM)) 
hDAT hNET hSERT 
MI-4 
 
3460±260 365±68 670±100 
SM-10 
 
ND ND 38,000±17000 
SM-11 
 
ND ND 17,000±7000 
SM-14 
 
15,600±2400 ND ND 
MI-17 
 
1298±36 5300±1341 284±66 
MI-17 
hybrid 
 
2129±177 >10,000 37±4 
 
Table 1.4. Novel MAT ligands discovered through MAT virtual screening.  
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1.6 Conclusion  
Structure-function studies performed on MATs were limited by the experimental 
techniques; and the recent computational efforts have proven highly valuable in 
understanding the functioning of these transporters more closely. The computational 
efforts to understand atomistic aspects of MAT function provided more structural clues in 
the design and development of new drugs. The design of novel drugs to treat various 
neurological disorders so far lacked a structural direction. Thus the structure-based VS 
efforts on MATs were undertaken, which led to the discovery of novel chemo types; and 
hit-to-lead optimization of these chemotypes helped increase their potency profile.   
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Chapter 2. 
DISCOVERY OF NOVEL SELECTIVE SEROTONIN 
REUPTAKE INHIBITORS THROUGH DEVELOPMENT 
OF A PROTEIN-BASED PHARMACOPHORE
† 
† Reproduced in part with permission from Manepalli, S.; Geffert, L.M.; Surratt, C.K.; Madura, J.D.           
J Chem. Inf. Model. 2011, 51(9), 2417-2426. 
 
The serotonin transporter (SERT), a member of the neurotransmitter sodium 
symporter (NSS) family, is responsible for the reuptake of serotonin from the synaptic 
cleft to maintain neurotransmitter homeostasis.  SERT is established as an important 
target in the treatment of anxiety and depression.  Because a high-resolution crystal 
structure is not available, a computational model of SERT was built based upon the x-ray 
coordinates of the leucine transporter LeuT, a bacterial NSS homolog.  The model was 
used to develop the first SERT structure-based pharmacophore.  Virtual screening (VS) 
of a small molecule structural library using the generated SERT computational model 
yielded candidate ligands of diverse scaffolds.  Pharmacological analysis of the VS hits 
identified two SERT-selective compounds, potential lead compounds for further SERT-
related medication development. 
2.1 Introduction  
Signaling between cells in the central nervous system is mediated by the 
controlled release and reuptake of neurotransmitters in the synapse.
1
 An excess or deficit 
of the monoamines serotonin, dopamine or norepinephrine in the synapse has been 
associated with various psychiatric and neurological disorders including depression, 
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anxiety, compulsivity, attention deficit hyperactivity disorder (ADHD), substance abuse, 
Parkinson’s disease and schizophrenia. 2-7  Control of synaptic monoamine levels is 
affected by the plasma membrane monoamine transporters (MATs), which terminate the 
action of these biogenic amines via reuptake into the presynaptic cell.  The mechanisms 
of action of drugs related to the above medical conditions typically involve the MAT 
proteins.  Tricyclic antidepressants (TCAs) such as imipramine (Tofranil
TM
), developed 
in the 1950s, alleviate depression by blocking serotonin and norepinephrine transporters 
(SERT and NET, respectively), thereby extending the lifespan of synaptic serotonin and 
norepinephrine. Unfortunately, the TCAs also block adrenergic, muscarinic acetylcholine 
and histamine receptors, responsible for a plethora of adverse effects.
8, 9
  Selective 
serotonin reuptake inhibitors (SSRIs), the next generation of antidepressants led by 
fluoxetine (Prozac
TM
) in the 1980s, carry far fewer adverse effects compared to the 
TCAs.  The SSRIs block SERT, but because the resultant surge of serotonin can activate 
any of 14 serotonin receptor types, this drug class is not without its own adverse 
effects.
10-12
 
 The driving force for MAT uptake of monoamine substrate is electrogenic, 
harnessing the inward Na
+
 gradient across the cell membrane.
13, 14
  The SERT, NET and 
DAT (dopamine transporter) are members of the neurotransmitter:sodium symporter 
(NSS) family as well as members of a larger group of Na
+
 and Cl
-
 dependent transporters 
known as the "solute carrier 6" (SLC6) family.
15
  The lack of a high-resolution 3-D MAT 
structure had hindered structure-function and therapeutic development efforts until a 
breakthrough was achieved in the form of crystallization of the bacterial NSS homolog 
LeuT, a leucine transporter.
16
  The LeuT x-ray structure has provided a template to build 
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credible MAT computational models.
16-21
  Although model quality increases with 
sequence identity with the template, structural similarity also plays a significant role.  
 In the absence of high-resolution 3D structures for SERT, development of a 
ligand based pharmacophore
22-25
 or QSAR
26-28
 are feasible alternatives to obtain 
structural information about the binding pocket.  Ligand-based approaches analyze a set 
of ligands and generate possible protein-ligand interaction patterns without knowledge of 
the protein structure.  A limitation of ligand-based approaches is that flexible alignment 
using dissimilar scaffolds is less reliable; knowledge of the bioactive conformation of at 
least one active molecule significantly improves alignment accuracy.
29
  These limitations 
can be overcome by using structure-based approaches, in which diverse scaffolds can be 
used to capture ligand interactions and the binding pocket environment in general.  
Docking, a structure-based technique, is capable of reliably predicting the bioactive 
conformation for a co-crystallized ligand.
30
  In the absence of an experimental 3D 
structure, however, a reasonable 3D model can be constructed for a receptor using 
crystallographic or NMR data from genetically and functionally related proteins.
31, 32
  
Comparative modeling correctly predicts the 3D fold of a protein in most cases 
and has often provided insight into the atomistic details of ligand binding.
33, 34
 Models 
created by this method have identified potential binding pockets, and have been 
employed for docking, structure-based pharmacophore generation and virtual screening 
(VS) to identify new ligands and their interactions with the protein.
33, 35, 36
  
Pharmacophore models, defined as a 3D collection of features essential for bioactivity of 
a ligand, have been widely employed.
37, 38
  The approach of combining a pharmacophore 
with VS has yielded novel structural scaffolds for ligands of a target receptor.
39-44
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Application of this technique with the DAT led to the identification of structurally novel 
VS "hit" compounds which, upon further modification, created a more potent analog 
through rational drug design.
33, 43, 45
  The present work describes the development of a 
structure-based pharmacophore and its VS utilization to identify novel ligand structural 
scaffolds that display SERT selectivity. 
 
2.2 Materials and Methods 
 Molecular modeling studies were performed out using dual-core 3.06 GHz iMac 
and 2.66 GHz quad-core Intel Xeon macpro. Construction and evaluation of homology 
models were performed using Discovery Studio 2.5.1.
46
 Docking and pharmacophore 
studies executed using the modules in Molecular Operating Environment (MOE 
2008.09); Chemical Computing Group Inc., S. S. W., Suite #910, Montreal, QC, Canada, 
H3A 2R7.) [
125
I]-RTI-55 and [
3
H]-serotonin were purchased from PerkinElmer (Foster 
City, CA).   The VS hit compounds were purchased from enamine and molport. The 
N2A-hDAT cell line was a gift from Dr. Margaret Gnegy (University of Michigan).   
HEK293 cells stably transfected with hSERT or hNET were prepared in collaboration 
with Dr. Mads Larsen and Dr. Susan Amara (University of Pittsburgh, Pittsburgh, PA).  
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2.2.1 Computational Methods 
2.2.1.1 Sequence Retrieval and Integrity Check of 
Template 
  The FASTA sequence of hSERT was downloaded from the Uniprot database 
(accession number P31645).
47
 The X-ray crystal structure of the Aquifex aeolicus protein 
LeuT (2a65) was used as the template and downloaded from the protein data bank 
(PDB).
48
  The template was checked for any missing residues/atoms using the “protein 
reports and utilities” module in DS 2.5.1.46 The protein report generated is a compilation 
of information about the resolution at which a protein was crystallized, the cell and space 
group of the crystal, atoms/residues missing the coordinates. In addition, it also provides 
a list of active sites, number of ligands, ions and solvent molecules cocrystallized with 
the biomolecule. This report can be viewed as concise portrayal about the defects in a 
crystal structure like nonstandard naming, structural disorder, atom connectivity and 
incorrect bond order of the amino acid residues. The report indicated that the residues 
Asn-133 and Ala-134 of the second extracellular loop (EL2) in LeuT (2a65) were 
missing the coordinates. As EL2 was noticed to play an important role in transport by 
forming the extracellular lid along with EL4 the coordinates of the missing residues in the 
loop (EL2) were built into the template in DS
16
. Since the modeled residues were in a 
loop, the most flexible regions in a protein, EL2 was subjected to the loop refinement 
protocol in DS to optimize the generated loop region.  
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2.2.1.2 Different Sequence Alignments 
SERT models were created even before LeuT crystallization, which is the closest 
homologue to MAT family. Even though different alignments were developed using 
LacY and other proteins as templates, the sequence alignments using LeuT as the 
template gained more attention due to its close evolutionary relationship with MATs 
(Table 2.1). Of these alignments, Yamashita et al. proposed the first alignment
16
 using 
Psi-BLAST
49
 with minor manual adjustments. No evolutionary information about MATs 
was used in generating this alignment and was generated only for the following human 
transporters--glycine, gamma-amino butyric acid, dopamine and serotonin leaving out 
norepinephrine transporter from the alignment. Following this, Beuming et al.
50
  
proposed a comprehensive sequence alignment using 177 eukaryotic and 167 prokaryotic 
protein sequences belonging to NSS family. The alignment considered evolutionary 
conservation pattern along with wealth of biological data available for NSS proteins. It 
considerably differed in TM 4,5,9 regions along with differences in EL 2,3,4 loops 
compared to Yamashita alignment, and was the most used alignment for model 
generation by different groups. Recently Celik et al.
51
 built SERT models using the 
proposed Yamashita’s and Beuming’s alignment along with an in-house developed 
alignment. Even though Celik’s alignment was not as comprehensive as Beuming’s; it 
considered residues Asp 98, Ala 169 and Ile 172 be pointing into the pocket and not into 
the lipid-facing region. None of the alignments proposed so far explicitly mentioned 
about modeling of the missing residues in EL2 that played a substantial role in substrate 
translocation. This study involved generation of another alignment by using “align 
sequence to template” protocol in DS. This protocol considers structural restraints into 
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account in the search for common motifs among the sequences. Though all these 
alignments looked similar in TM regions, minor differences are present in loop regions 
that influence studies performed to study dynamic aspects of these proteins. The addition 
of missing residues to LeuT used in alignment modified the sequence identity by a 
marginal extent (24%) compared to other alignments, but it is regarded generally as the 
more the sequence identity with the template used the better the model generated
52
. The 
objective of using all four alignments was to identify which alignment produces a model 
suitable for our study. 
  
 
 
Table 2.1. Percent sequence identity and sequence similarity among different 
alignments used to build SERT models. 
 
 
 
 
 
 Manepalli 
alignment 
Celik 
alignment 
Beuming 
alignment 
Yamashita 
alignment 
% Sequence 
identity 
 
 % Sequence          
similarity 
23.9 
 
 
46.7 
22.9 
 
 
45.6 
20.5 
 
 
42.6 
20.0 
 
 
42.4 
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2.2.1.3 Construction of SERT Homology Models 
Different hSERT models were then created using the Align2d methodology
53
 and 
the three previously proposed sequence alignments.
16, 50, 51
  
2.2.1.3.1 hSERT Model 1: Manepalli et al. Alignment  
The sequences of hSERT and modified LeuT were aligned using the "align 
sequence to templates" protocol in DS.  An alignment similar to Celik et al.
51
 was 
generated, with minor manual modifications further increasing the sequence identity with 
LeuT.  N- and C-terminal overhangs were deleted, increasing sequence identity to 24% 
and sequence similarity to 47%.  The hSERT model sequence began at Arg-79 in the N-
terminal tail and ended with Lys-605 in the C-terminal tail (Figure 2.1).  The "build 
homology model" protocol in DS, which employs MODELLER version 9v4,
31
 was used 
to construct 20 hSERT models.  The models were further refined and ranked by discrete 
optimized protein energy (DOPE) score and the model with the best DOPE score was 
designated as “Model 1”.
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Figure 2.1. Alignment of LeuTAa and hSERT amino acid sequences used to build 
Model 1.  Identical (blue) and similar (yellow) aligned residues are indicated. The dots 
and stars correspond to residues lining S1 and S2 pockets respectively.  Transmembrane 
and connecting loop topology is displayed above the sequences.  Gaps relative to the 
other sequence are represented by dots.  Position of the residue in its respective chain is 
indicated before and after each line of sequence.
  53 
2.2.1.3.2 hSERT Model 2: Beuming et al. Alignment  
The hSERT query sequence and modified LeuT were loaded into DS and aligned 
as described by Beuming et al. (Figure 2.2).
50
  Terminal residues not having the 
matching template coordinates at both ends were omitted, and 20 models were built and 
assigned DOPE scores as described above.  Models based on this alignment resulted in 
EL2 positioned directly above the substrate permeation pore, which would likely have 
influenced ligand docking.  The dangling EL2 was adjusted using the DS loop refinement 
protocol.  Models were then evaluated using the "verify protein" protocol, which assesses 
the score of each residue in the known 3D environment.  This was followed by 
superposition of the hSERT model onto LeuT to check for TM domain coincidence.  The 
final version was designated "Model 2". 
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Figure 2.2. Alignment of LeuTAa and hSERT amino acid sequences following Beuming 
alignment.  Identical (blue) and similar (yellow) aligned residues are indicated.  Transmembrane 
and connecting loop topology is displayed above the sequences. Position of the residue in its 
respective chain is indicated before and after each line of sequence. 
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2.2.1.3.3 hSERT Model 3: Yamashita et al. Alignment 
The hSERT query sequence and modified template were aligned as proposed by 
Yamashita et al. (Figure 2.3).
16
  N- and C-terminal overhangs were deleted, leaving 527 
hSERT residues.  Twenty models were created and the best model resulting from this 
alignment was designated as "Model 3". 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.3. Alignment of LeuTAa and hSERT amino acid sequences following 
Yamashita alignment. Identical (blue) and similar (yellow) aligned residues are 
indicated.  
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2.2.1.3.4 hSERT Model 4: Celik et al. Alignment 
Twenty hSERT models were built with DS as described above but following the 
proposed Celik et al. alignment
51
 (Figure 2.4), which offered a sequence identity match 
comparable to the Manepalli alignment and greater than the Beuming and Yamashita 
alignments.  A 527-residue hSERT polypeptide was used to develop “Model 4”, as 
described for Model 1.  
 
 
 
 
 
 
 
 
 
Figure 2.4. Alignment of LeuTAa and hSERT amino acid sequences following Celik 
alignment. Identical (blue) and similar (yellow) aligned residues are indicated.  
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2.2.1.4 Model Refinement and Validation 
 Five models among the twenty homology models created from each alignment 
were chosen based on Discrete Optimized Protein Energy (DOPE) scores. It is a score 
generated by MODELLER, which is an atomistic-based statistical potential for model 
evaluation and structure prediction.
54
 This conformational energy measure reflects the 
stability of a model relative to other models generated. Following this, the stereo chemical 
quality of the five preferred models was assessed with the validation server that is used to 
evaluate structures deposited into PDB.
55
 This server uses NUCheck
56
, PROCHECK
57
 and 
SFCHECK
58
 programs to check various stereo chemical features that symbolize a 
structure stability. From each group of five, two models were then chosen based on their 
having the fewest outliers on the phi-psi angle Ramachandran plot.  The chosen two 
models from each alignment were evaluated for 3D fold (tertiary structure), using the 
“verify protein” protocol in DS.  This protocol reduces 3D structures to a simplified 1D 
representation, compares to the 1D amino acid sequence, and assigns a score. This score 
measures how compatible a three-dimensional fold is with its one-dimensional sequence. 
If the score calculated is close to the expected high it implies that generated model has an 
optimal 3D-fold respective to its sequence and lower scores highlight regions that are 
poorly modeled and their fold is not optimal to its amino acid sequence. The models 
selected from the previous evaluation parameters were checked for TM domain assembly 
and ligand binding pocket volume by superposing the SERT models onto the LeuT crystal 
structure using MOE (Figure 2.5).
59
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Figure 2.5. Polypeptide backbone superposition of the four homology SERT models.  
Good overall spatial overlap was observed for Models 1 (Manepalli et al.; red), 2 
(Beuming et al.; blue), 3 (Yamashita et al.; yellow) and 4 (Celik et al.; green), with 
essentially perfect overlap of TM domains. EL2 (arrow) was the most divergent region 
among the four models. 
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A single hSERT model was selected from each of the groups resulting in four final 
models that were generated using different alignments.   The all-atom force field 
AMBER99 
60, 61
 was used to add hydrogen atoms and partial charges to the models.   
Keeping the non-hydrogen atoms fixed in space, hydrogen atoms were minimized with a 
convergence criterion of 0.05 kcal/mol.  The final hSERT models chosen from each 
alignment were further optimized to minimize the outliers and avoid unnecessary protein 
contacts.  Of the four models, Model 1 had the smallest RMSD on superposition with 
LeuT and maximal ligand binding pocket volume. 
  
2.2.1.5 Ligand Binding Site Identification  
 The alpha site finder function of MOE 2008.09 was used to identify possible 
ligand binding sites in Model 1.  The site finder is purely geometric; no energy terms are 
used.  Alpha spheres within the hSERT model that were too exposed to solvent were 
eliminated; spheres that corresponded to locations of tight atomic packing in the model 
were retained.  Spheres were classified as either "hydrophobic" or "hydrophilic" 
depending on the potential for hydrogen bonding.  Following the default settings, alpha 
spheres were clustered to produce a collection of putative binding sites that are ranked 
according to the number of hydrophobic atoms within contact distance of the spheres. The 
sites corresponding to the S1 and S2 pockets were identified and dummy atoms were 
created in the pockets to specify the algorithm to dock the ligands. As the S2 pocket is a 
huge cavity exposed towards the extracellular space, a sphere with a radius of 8 Å was 
created to constrain docking poses in keeping with recent reports (Figure 2.6).
18, 21
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Figure 2.6.  A sphere (red) of 8 Å to constrain docking poses in extracellular exposed 
S2 pocket. hSERT displayed as blue TM helices. 
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2.2.1.6 Docking of Known Antidepressants 
 Ligand coordinates for sixteen antidepressants (Figure 2.7) were obtained from the 
small molecule crystal database CCSD (Cambridge Crystallographic Structural 
Database).
62, 63
 Ligands having no coordinates were drawn using MOE.  Partial charges 
and hydrogen atoms were added to all ligands using Merck Molecular Force Field 94X 
(MMFF94x).
64-66
  Ligand geometry was optimized via energy minimization with a 
conjugated gradient truncated Newton optimization algorithm with convergence criteria = 
0.01 kcal/mol, ε = 1.  Leucine or selected TCA drugs were first docked with the LeuT 
model to test for consistency with the reported cocrystal structures.
16, 21
 Atom placement 
methods including proxy triangle, alpha triangle and triangle matcher were employed, as 
were refinement techniques using grid-based and force field-based methods.  The 
combination that produced poses very close to the crystal structure  (<1Å) was chosen for 
hSERT docking.   Interaction plots for all docked poses of different antidepressants in 
hSERT were generated using the MOE ligand interaction module.
67
  A consensus of 
residues and their predicted ligand interactions was developed and used in creating the 
pharmacophore features for the vestibular ligand-binding pocket.  
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Figure 2.7. Chemical structures of SERT inhibitors (antidepressants) used to develop 
the pharmacophore.  
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2.2.1.7 Development of 4-point SERT S2 Pharmacophore  
 A pharmacophore feature was generated at each amino acid side chain – ligand 
interaction point obtained from initial docking iterations.  Pharmacophore points F1, F2, 
F3 (each with a radius of 1 Å) and F4 (radius = 1.5 Å) were delineated to better 
encompass the hydrophobic features of the docked ligands.  An excluded volume was 
created, and the algorithm assigned a penalty to poses that encroached on this space.  The 
final pharmacophore product was tested using a database containing known hSERT 
ligands and decoy ligands.  The pharmacophore model successfully discriminated the 
classic hSERT ligands from the decoys (Table 2.2). 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2.2. List of top ten compounds (binders) identified in the evaluation of 
pharmacophore.  
 
Compound Affinity dG Score 
(kcal/mol) 
Fluoxetine -9.23 
Sertraline -9.05 
Paroxetine -8.92 
Citalopram -8.75 
Fluvoxamine -8.24 
Zimeldine -8.07 
Venlafaxine -7.67 
Trazadone -7.19 
Imipramine -6.87 
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2.2.1.8 Virtual Screening of ZINC Database 
 An 18 million entry “all-purchasable” subset of the ZINC database containing was 
downloaded.
68
  The subset was “washed” by importing the collection into MOE, which 
removes unwanted salts, ions and disconnected molecular fragments from the database.  
The Lipinski’s Rule of Five descriptor available in MOE was applied to the database to 
remove nondrug-like molecules.
69
  The resulting database was then searched for 
compounds containing toxic groups and eliminated by using toxic moiety descriptor in 
MOE. From this database a subset containing approximately one million compounds was 
selected for further use.  The tautomers and protomers of these entries were generated at 
physiological pH.   Using the “import conformation” module of MOE, different 
conformations were generated and minimized using the MMFF94x force field; 
conformations with strain energy 4 kcal/mol or more above the lowest energy 
conformation were discarded.  This final database was screened using the 4-point SERT 
S2 pharmacophore.  “Hit” compounds acceptable to the pharmacophore filter were further 
screened to ensure the presence of halogens and a molecular weight < 350 daltons, 
features common to most of the known antidepressants.  These steps yielded a pool of 
4,097 hit compounds.  Three hSERT docking iterations were performed with this pool of 
structures.  Affinity scores < -6.0 kcal/mol plus visual inspection was used to condense the 
pool to 68 candidate ligands (Figure 2.8).  Of these, 10 of the top-ranked 15 compounds 
[(coded “SM-1” through “SM-15”), Figure 2.9] were procured from various sources and 
pharmacologically tested.  
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Figure 2.8. Different sequential filters used in structure-based virtual screening of 
SERT. 
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Figure 2.9. Chemical structures of first batch of hits identified.  
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2.2.2 Experimental Methods 
The experimental (pharmacological assays) were performed by Ms. Laura M. 
Geffert from Dr. Christopher K. Surratt lab from Mylan School of Pharmacy, Duquesne 
University. 
2.2.2.1 In vitro VS Compound Binding Screen. 
Compounds identified from the virtual screen were purchased and dissolved in 
100% DMSO to a concentration of 10 mM.  Initial one-point competition binding assays 
0.1 nM of the 
radiolabeled cocaine analog [
125
I]-RTI-55, a radioligand with high affinity at all three 
MATs.   Stably transfected HEK293-hSERT membranes or N2A-hDAT or HEK293-
hNET whole cells were employed for all binding assays.  Non-specific binding was 
hDAT or hNET assays, respectively.  Screening results were analyzed with one-way 
ANOVA (P < 0.05) with a post-hoc Dunnett's Multiple Comparison Test.  
 
2.2.2.2 hSERT Membrane Binding Assay   
hSERT binding affinities were obtained by displacement of [
125
I]-RTI-55 in 
membrane binding assays.  Membrane was prepared from stable hSERT-HEK cells grown 
at 37˚C in a 5% CO2 environment on 150 х 25 mm plates.  At 95% confluence (3 days of 
growth), cells were washed twice with 10 mL cold phosphate-buffered saline (DPBS).   
An additional 10 mL of DPBS was added and cells were harvested by scraping and 
transferred to cold centrifuge tubes (15 mL), followed by centrifuging for 10 min at low 
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speed (700 x g).  After removal of the supernatant, the cell pellet was resuspended in 500 
uL cold TE buffer (50 mM Tris, 1 mM EDTA, pH 7.5).  Following centrifuging for 30 
min at 100,000 x g at 4˚C, the supernatant was discarded and the pellet was frozen for 
later use or resuspended in ice-cold binding buffer (50 mM Tris, pH 7.5, 100 mM NaCl).  
Each sample was analyzed for protein content using the Bradford protein assay.  For 
competition binding, membrane was incubated with [
125
I]-RTI-55 (0.1 nM concentration) 
and increasing concentrations of cold competitor (1 nM to 1 mM), or 10 μM paroxetine to 
measure non-specific binding.   Reactions were carried out in 12 х 75 mm borosilicate 
glass tubes with gentle shaking at room temperature for 1 hour and terminated by rapid 
filtration through GF/B filters (Schleicher and Schuell, Keene, NH) presoaked in 0.5% 
polyethylenimine solution (v/v).  Filters were washed twice with 5 mL cold 50 mM Tris 
buffer and transferred to vials.  Radioactivity was determined using a Beckman gamma 
counter.  For saturation binding assays, data were analyzed with GraphPad Prism 5.0 
software.  IC50 values were generated and converted to Ki values using the Cheng-Prusoff 
equation (Ki = IC50/ (1+ ([RTI-55]/Kd RTI-55)).
70
  
 
2.2.2.3 hDAT and hNET Whole Cell Binding Assays.  
 Whole-cell competition binding assays were performed for hDAT and hNET 
using stable hDAT-N2A or hNET-HEK293 cell lines, respectively, grown at 37˚C in a 5% 
CO2 environment.  Cell monolayers were grown in 24-well plates to >90% confluence.  
Cells were washed twice with 1 mL of KRH buffer (25 mM HEPES, pH 7.3, 125 mM 
NaCl, 4.8 mM KCl, 1.3 mM CaCl2, 1.2 mM MgSO4, 1.2 mM KH2PO4, 5.6 mM glucose) 
supplemented with 50 mM ascorbic acid (KRH/AA).  Cells were incubated for 15 minutes 
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with 1 nM [
125
I]-RTI-55 supplemented with tropolone (total volume of 500 uL) along with 
(hNET).  Following incubation, cells were washed twice with 1 mL KRH/AA buffer, then 
treated with 1 mL 1% SDS with gentle shaking at room temperature for 1 hour.  Cell 
lysates were transferred into vials.  Radioactivity was determined using a Beckman 
gamma counter and analyzed using GraphPad Prism 5.0 as described above.  
2.2.2.4 Serotonin Uptake Inhibition Screen.   
One-point competition binding assays were performed using stably transfected 
HEK293-hSERT whole cells grown to >90% confluence on 24-well plates.  Cells were 
followed by addition of 10 nM [
3
H]-serotonin.  After an additional 5 min, cells were 
washed twice, then treated with 1% SDS and shaken for 1 hr.  Lysates were transferred to 
5 mL scintillation fluid and radioactivity was detected using a Beckman liquid scintillation 
counter.  Non-
clomipramine.  
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2.3 Results and Discussion 
2.3.1 Model Construction and Refinement 
Four discrete amino acid sequence alignments with LeuT were generated that 
primarily differed in the loop regions.  Manual refinement of the alignments was 
conducted to remove gaps within the TM regions.  Rotamers of the residue side chains 
lining the hSERT halogen-binding pocket were selected based on their ability to form a 
sub-pocket, as these residues have been reported to be important for binding of certain 
SSRIs.
21
  A total of 80 SERT homology models were built using Discovery Studio (DS) 
2.5.1.  Five models from each alignment (20 models total) having the lowest DOPE score 
were chosen for further evaluation. The models were also deposited into the PDB 
evaluation server and assessed with respect to stereochemical quality.
55
 The plots 
generated by the server were evaluated for unusual phi-psi angles, bond lengths, bond 
angles and van der Waals contacts (Figure 2.10).  Two models from each alignment were 
selected for further evaluation, specifically their fitness in a 3D environment assessed by 
Profiles-3D.  This DS module assesses the protein’s tertiary structure compatibility with 
its sequence.  Finally, spatial overlap of the model and template polypeptide backbone 
atoms was examined to check the integrity of the model's TM domains and the volume of 
its binding pocket.  On this basis, "Model 1" was chosen for further studies.  
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Figure 2.10. Ramachandran plot analysis of the stereo chemical parameters of model 
1. Residues Arg 312 (EL 3) and Val 379 (TM 7) were the outliers and are far from the S2 
binding pocket. 
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Residues in most favoured regions  [A,B,L]              435  94.0%
Residues in additional allowed regions  [a,b,l,p]        25   5.4%
Residues in generously allowed regions  [~a,~b,~l,~p]      1   0.2%
Residues in disallowed regions                            2   0.4%
                                                       ---- ------
Number of non-glycine and non-proline residues          463 100.0%
Number of end-residues (excl. Gly and Pro)                2       
Number of glycine residues (shown as triangles)          41       
Number of proline residues                               21       
                                                       ----       
Total number of residues                                527       
Based on an analysis of 118 structures of resolution of at least 2.0 Angstroms
and R-factor no greater than 20%, a good quality model would be expected 
to have over 90% in the most favoured regions.
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2.3.2 Docking and Pharmacophore Feature Generation 
 The MOE alpha site finder was used to identify possible ligand sites in Model 1.   
A site exposed to the extracellular space was chosen based on evidence for inhibitors 
binding in this vestibule.
21
 The combination of proxy triangle as the placement method 
and force field refinement with an affinity scoring function yielded MOE docking poses of 
leucine into LeuT with an RMSD of 0.31 Å.  The same combination was employed to 
dock the 16 structurally diverse antidepressants that possess a large range of SERT 
binding affinities (0.1 nM - 9100 nM).  It is acknowledged that certain SSRI ligands used 
in the docking have been reported to access the interior S1 substrate pocket 
71
; however, 
the VS pocket employed in this study contained elements of the vestibular (S2 substrate) 
pocket and the halogen-binding pocket (HBP) (Figure 2.11). The latter pocket is defined 
in part by hSERT residues Leu-99 (TM 1), Trp-103 (TM 1) and Ile-179 (TM 3).  The 
ligand-accessible region of the HBP (green cloud) is adjacent to that of the S2 pocket 
(orange cloud); the HBP appears to be important for recognition of halogen-containing 
inhibitors. Poses in which the halogen atom of the ligand was directed toward this pocket 
were thus favored. 
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Figure 2.11. Ligand-accessible regions of SERT substrate and inhibitor binding 
pockets.  Regions available to ligands in the S1 (blue), S2 (orange) and HBP (green) 
pockets are displayed as surfaces.  The pocket employed for virtual screening combined 
the S2 and HBP.  Residues defining each pocket are displayed as sticks (atomtype color).  
For clarity, the TM1 (red), TM3 (orange), TM6 (green), TM8 (cyan) and EL4 (pink) 
helices are highlighted.   
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2.3.3 Development of 4-point SERT S2 Pharmacophore  
Overlaying the highest-ranked poses of different antidepressants a “common 
interaction pattern” was generated. Residues identified as common interaction points were 
then chosen to develop a 3D pharmacophore. Pharmacophore feature F1 of radius 1 Å was 
created midway between Arg-104 (TM 1) and Glu-493 (TM 10) to capture possible ionic 
or H-bond interactions, particularly with protonated ligand nitrogen atoms.   Previous 
reports of SERT-based pharmacophore models indicated the importance of a positively 
charged nitrogen atom.
72, 73
 Feature F2 (radius 1 Å) was created in the vicinity of Lys-490 
(TM 10) to capture possible H-bond interactions.  The lysine side chain is among the more 
flexible of the naturally occurring amino acids; 78 rotamers were possible for Lys-490.   
The rotamer oriented toward the vestibular pocket, analogous to Asp-401 in LeuT, was 
chosen to capture possible interactions with ligands.   Asp-401 is reported to interact with 
different antidepressants in LeuT crystal structures
21
; thus, Lys-490 would be expected to 
play a similar role in hSERT.  Feature F3 (radius 1 Å) was created to capture H-bond or 
cation-π interactions with Tyr-107 (TM 1).  Residues 104-106 of hSERT TM 1b are 
analogous to LeuT residues 30-32, although hSERT Tyr-107 and LeuT Val-33 differ 
substantially regarding the nature of potential ligand interactions.  Feature F4 (radius 1.5 
Å) in the HBP was designed for hydrophobic interactions believed to be important in 
recognizing SSRIs.  Residues lining the pocket are conserved between hSERT and 
LeuT.
21
  Substitution of the hSERT TM 3 residue Ile-179 (Ile-111 in LeuT) with alanine, 
phenylalanine or aspartic acid increased SSRI substrate uptake inhibition potency by 7 – 
1080 fold.
21
  The TM 1 mutations Ala77Gly in hNET and Ala81Gly in hDAT were 
observed to improve SSRI affinity, suggesting a negative influence of the methyl side 
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chain of alanine on SSRI binding.  Finally, an exclusion volume was added to make the 
pharmacophore more stringent and selective (Figure 2.12).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.12. Four-point pharmacophore for SERT S2 pocket displayed along with 
excluded volume. The pharmacophore employed for VS was comprised of features 
(colored spheres).  F1: Donor/acceptor (red).  F2: Acceptor (pink).  F3: Cation/acceptor 
(blue).  F4: Hydrophobic / π ring (green) and excluded volume (grey).   
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2.3.4 Virtual Screening and Pharmacological Testing 
Approximately one million members of the ZINC small molecule structural library 
database
68
 were screened with the 4-point S2 SERT pharmacophore for possible "hit" 
compounds.  A total of 4097 molecules were acceptable to the pharmacophore filter.   
Docking of this subset into the SERT model followed by monitoring of affinity dG scores 
with visual inspection of the resulting poses yielded 68 preferred compounds. Due to lack 
of availability, only ten of the top 15 compounds (labeled SM-1 to SM-15) were initially 
tested for hSERT, hDAT or hNET affinity in single point in vitro binding assays.  Two 
compounds, SM-10 and SM-
[
125
I]-RTI-55 from hSERT membranes, indicating measurable hSERT affinity. At the 
same final concentration, these two compounds did not displace the radioligand at hDAT 
or hNET cells. (Figure 2.13)  SM-10 and SM-11 were further characterized at hSERT 
HEK293 membranes in competition assays to obtain Ki values for inhibition of [
125
I]-RTI-
55 binding. The binding affinity values for SM-10 and SM-11 towards hSERT are 38 ± 17 
μM and 17 ± 7 μM respectively with SM-11 binding stronger than SM-10 (Figure 2.14). 
SM-10 and SM-11 were also screened for the ability to inhibit uptake of [
3
H]-serotonin by 
intact hSERT HEK293 cells.  Because no inhibition of [
3
H]-serotonin uptake was detected 
50 values 
were not obtained (Figure 2.15).  
But surprisingly SM-14 (Figure 2.16) was found to be DAT selective by 
displacing [
125
I]-RTI-55 at hDAT cells alone.  A DAT binding affinity Ki value of 15.6 ± 
2.4 μM (mean ± s.e.m.) and a dopamine uptake inhibition potency IC50 value of 10.5 ± 4.6 
μM were observed. (Figure 2.17 and Figure 2.18) Given the high sequence similarity (~ 
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50%, as calculated with BLAST) among the three-hMATs, finding a specific inhibitor that 
targets a single transporter is a challenging task.  VS is more precarious with the 
additional inhibitor binding pocket uncertainty associated with a homology model built  
using a template sharing < 30% sequence identity. Because of this handicap, and because 
the goal of the study was to identify SERT ligands of novel structural scaffold, a very high 
concentration of VS hit compound relative to the SERT ligand radiotracer (100,000-fold) 
was employed in the pharmacologic screen.  The observation that most of the VS hits 
showed no ability to displace the radioligand at the SERT-HEK cells confirms that the 
huge molar ratio of VS compounds: radiotracer was itself insufficient for decreasing 
radiotracer binding (i.e., some SERT affinity is required to register a response in this 
assay).   
The two VS hits pharmacologically verified as SERT ligands displayed 
micromolar Ki values.  These binding affinities are very low compared to the nanomolar 
or better SERT affinities of certain SSRI therapeutics.  Inhibition of serotonin uptake was 
uptake inhibition potency is often lower than binding affinity for a given MAT inhibitor, 
possibly due to differences in MAT conformational or population requirements for the two 
processes.
74, 75
 -10 or SM-11 concentration employed may be above the 
threshold for detecting SERT ligand binding but below the threshold for detecting 
serotonin uptake inhibition. 
Micromolar affinities for VS hit compounds are common when homology models 
are employed.
76-83
  From this research team, the first reported VS effort based on a DAT 
homology model yielded a hit compound (MI-4) with low micromolar DAT affinity and 
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slightly better (high nanomolar) SERT affinity. Without modification, this compound 
displayed antipsychostimulant and antidepressant properties (Ref. 43 and unpublished 
data).  The same VS effort using a DAT model yielded a hit compound (MI-17) with a 
SERT Ki value of 284 nM.  An MI-17 analog designed to increase SERT selectivity 
resulted in a compound with a SERT Ki value of 37 nM, and SERT: DAT and SERT: 
NET selectivity ratios of 50 and over 200 respectively.
45
 Thus, VS hit compounds with 
micromolar affinities appear to be useful as lead compounds for medication development. 
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Figure 2.13. VS hit compound in vitro MAT binding screen.  
final concentration were tested for the ability to inhibit [
125
I]-RTI-55 binding at hSERT 
HEK293 cells (top panel), hDAT N2A neuroblastoma cells (middle panel), or hNET 
HEK293 cells (bottom panel).  Non-specific binding was assessed by the presence of 10 
respectively.   Data represent n=3 independent experiments performed in duplicate.  Data 
are presented as the mean ± s.e.m. and were analyzed by one-way ANOVA with 
Dunnett’s multiple comparison post-hoc test.   *P < 0.05 vs. total binding for that assay.  
***P < 0.0001 vs. total binding for that assay. (Provided by Ms. Laura M. Geffert) 
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Figure 2.14.    Saturation binding of VS hit compounds. SM-10 (closed circles) and 
SM-11 (open circles) at hSERT HEK293 cells.  Binding affinity Ki values were 
determined via displacement of [
125
I]-RTI-55.  n=3 experiments. (Provided by Ms. Laura 
M. Geffert) 
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Figure 2.15. VS hit compound in vitro serotonin uptake inhibition screen.   
3
H]-
serotonin uptake by hSERT HEK293 cells.  Non-specific radioligand uptake was assessed 
experiments performed in duplicate.   Data are presented as the mean ± s.e.m. and were 
analyzed by one-way ANOVA with Dunnett’s multiple comparison post-hoc test.  *P < 
0.05 vs. total uptake for that assay.  **P < 0.001 vs. total uptake for that assay. (Provided 
by Ms. Laura M. Geffert) 
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Figure 2.16. Structures of hits identified through virtual screening SM-10, SM-11 
and SM-14. 
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Figure 2.17. Saturation binding of VS hit compounds SM-14 at hDAT N2A cells.  
Binding affinity Ki values were determined via displacement of [
125
I]-RTI-55.  (n=3 
experiments). (Provided by Ms. Laura M. Geffert) 
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Figure 2.18. Dopamine uptake inhibition potency of VS hit compound SM-14 at 
hDAT N2A cells.  Uptake inhibition Binding affinity Ki values were determined via 
displacement of [
125
I]-RTI-55.  (n=3 experiments). (Provided by Ms. Laura M. Geffert) 
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2.4 Structural Novelty of SM Hit Compounds 
Given their structural flexibility, SM-10, SM-11 and SM-14 greatly differ from the 
SSRIs and TCAs that were employed to develop the pharmacophore (Figure 2.16). The 
Tanimoto similarity coefficient was calculated for the three hits to identify the 
dissimilarity compared to the known inhibitors (SSRI, TCA). A coefficient of less than 0.6 
was calculated, which signify the structural novelty of these hits.  More specifically, the 
SSRIs and TCAs currently being used contain either rigid or fused rings when compared 
to the flexible SM hits. This flexibility would provide the additional advantage of reaching 
the higher affinity substrate pocket. The similarities between the SSRIs and SM hits are 
the presence of a charged amine group and halogen atoms, which are required for SERT 
inhibition. In addition, the flexibility of these molecules with well separated rings presents 
additional attach points to optimize SERT affinity and can be developed as multi site 
drugs. 
 
2.4 Conclusion 
To our knowledge this is the first study to identify novel SERT-selective reuptake 
inhibitors through VS performed with an hSERT homology model.  Conventional drug 
development usually involves creation of analogs of established ligands for a given 
receptor.  In contrast, the VS approach affords the possibility of discovering ligands with 
very different scaffolds, ligands that in all likelihood would never be otherwise identified 
for that receptor.  In the case of the SERT, inhibitors of novel scaffold provide new 
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opportunities for development of rationally designed multi-site drugs (e.g., SERT/5-
HT2A/5-HT3 blockers) that address the therapeutic goal while mitigating the adverse 
effects associated with the SSRI drug class.  It is anticipated that the two SM compounds 
described herein should serve as lead compounds toward the treatment of depression, 
anxiety, and other serotonin-related disorders.    
 
2.5 Future Directions 
Lead optimization is the next step after lead identification in drug discovery. In 
this study two novel scaffolds selective to SERT were identified. Of the two leads, SM-10 
has a better affinity but it has three stereo centers. Purchasing the different possible 
stereoisomers and testing them seems to be the next logical step. As the leads were low 
affinity binders, hit-to-lead optimization has to be performed to identify higher affinity 
analogues. Even though these leads were identified through S2 pocket virtual screening, 
the location of the binding pocket and the relative orientation of the ligand in the 
transporter are speculative. As these novel ligands are flexible an assumption can be made 
as part of these ligands may reach S1 pocket with rest of the molecule docked into S2. So 
the studies that identify the binding orientation and modification of the scaffold extend 
this study.  
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Chapter 3. 
ELUCIDATION OF BINDING PROFILE SIMILARITIES 
AMONG STRUCTURALLY DIVERSE INHIBITORS OF 
DOPAMINE TRANSPORTER 
 
3.1 Introduction 
 
Dopamine transporter (DAT), norepinephrine transporter (NET) and serotonin 
transporter (SERT) belong to the family of monoamine neurotransmitters (MATs). They 
play an important role in maintaining the neurotransmitter levels that control mood, 
hunger etc.
1
  Imbalance in the levels of neurotransmitters is the primary cause for several 
psychological disorders like addiction, depression etc.  Various experimental studies 
performed imply that DAT is primarily responsible, for the reward/reinforcing properties 
associated with psychostimulant substances like cocaine and amphetamines.
2-5
  
 Very little is known about how these addictive substances interact with DAT and 
block dopamine reuptake. Structurally, diverse inhibitors interact with DAT by binding to 
different non-overlapping binding sites.
6, 7
 To identify the exact location of binding 
pocket, photoaffinity probes of dissimilar scaffolds were developed. In the presence of 
ultra violet light, they form a covalent bond with the amino acid residues in DAT, which is 
then identified by mass spectrometric studies (Figure 3.1). 
Analogues of the tropane-based 
8-17
 with very flexible piperidine
18
 and piperazine 
analogues
19-24
 were developed and used as photo probes (Figure 3.2) with less focus on 
non-tropane based analogues.
25-27
  Photoaffinity probes based on the tropane analogues 
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covalently bond to residues far from the binding pocket and may not provide the precise 
location. So, the probes with photoaffinity groups substituted directly on the inhibitor 
were developed to provide a much better picture. 
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Figure 3.1. Schematic representation of the photoaffinity labeling of a protein. The 
target protein (DAT) is represented by a blue rectangle, photoaffinity ligand (red triangle) 
and a photoactive group (green star). Upon irradiation by ultra violet light, photoactive 
group on photoaffinity ligand forms a covalent bond with DAT. The protein is lysed and 
the polypeptide fragments are analyzed by mass spectrometry to identify the location of 
covalent linkage.  
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Figure 3.2. Structures of tropane- and piperazine-based DAT photoaffinity ligands.  
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3.2 Methods 
 
Numerous analogues synthesized in the scheme towards final photoprobe were 
also included to better understand the structure activity relationship (interaction pattern) 
with DAT. The 3D-coordinates of parent compounds and analogues of the three diverse 
scaffolds (groups) were drawn in molecular operating environment (MOE).
28
 Partial 
charges and hydrogen atoms were added to all ligands using Merck Molecular Force Field 
94X (MMFF94x).
29, 30
 The geometry of these ligands was then refined using energy 
minimization module with a convergence criteria of 0.01 kcal/mol in MOE.  
 A DAT homology model previously generated was employed to dock these 
compounds.
31
 As the binding pocket of these inhibitors was unknown and only 
extracellular pocket (S2) was accessible to all the analogues, the focus of the study 
involved docking these ligands into the S2 pocket.  Moreover, S2 site was proposed as a 
staging area for inhibitors before sliding further into the S1 pocket.
32
  
 The biomoleular force field, assisted model building with energy refinement 
(AMBER 99) was used to add partial charges and hydrogen atoms to the homology model 
of DAT.
33, 34
 The previously proposed S2 pocket was chosen as the site to dock ligands, 
and a sphere of 8 Å radius was constructed in this pocket.   
Three different docking runs were performed for each group, which included the 
parent compound and their analogues. The separate databases generated for each group 
were then merged together into a single database. The compound database was then 
provided as an input for the protein ligand interaction fingerprint (PLIF) panel in MOE. 
The PLIF tool generates a population histogram that represents the protein-ligand 
interaction pattern. PLIF is a computational tool to encapsulate the interaction pattern by 
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generating fingerprints of docked poses. A fingerprint is a sequence of binary bit strings 
that associates different structural features of a molecule, and is a commonly employed 
method in various ligand-based approaches.
35-37
    
 
3.3 Results and Discussion 
 
 All analogs towards the synthesis of final photoactive probes for dissimilar 
scaffolds were also included in the study to understand the structure-activity relationship 
(SAR).
25-27
  An assumption was made that all these diverse inhibitors bind in the same 
pocket, and were docked into the S2 pocket of DAT.  
The homology model of DAT used in this study was constructed using the 
occluded conformation of LeuT (pdb id:2a65) with the primary substrate pocket (S1) 
completely blocked by the extracellular gates.
38
 As the S2 pocket is large and exposed 
towards the extracellular space, a sphere was created to constraint the docking poses in 
DAT. Docking runs were performed to generate various docked poses in MOE.  
The fingerprints were then generated for each docked pose using PLIF analysis. It 
considers six different non-bonded interactions [side chain hydrogen bonds 
(donor/acceptor), back bone hydrogen bonds (donor/acceptor), ionic interactions and 
surface contacts] into account to generate a fingerprint for each pose. Clustering of these 
fingerprints was then performed to generate a histogram that showed the interaction 
pattern of each docked pose. 
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Bupropion:  A number of bupropion analogues with varying substitutions on aromatic 
ring were synthesized (see Figure 3.3).
39, 40
 It was perceived that halogen substituted 
analogues had higher DAT affinity, which implies that bulky substitutions were well 
tolerated. It was also noticed that the parent compound bupropion (441 nM) is seven fold 
stronger than its photoprobe analog, SADU-3-72 (3071 nM) in DAT N2A neuroblastoma 
cells.
40
  The fingerprint analysis (Figure 3.5) identified that the terminal amino group 
interacts with Asp 312 (TM6) and the azide group forms an ionic bond with Asp 475 
(TM10), which wasn’t detected for bupropion (Figure 3.4). A clear trend of increased 
interaction profile with Asp 475 was identified (Figure 3.5) for the photoprobe. The trend 
suggested that the highly reactive nitrene generated upon UV light would covalently link 
to Asp 475.  
 
 
 
 
 
 
 
 
Figure 3.3. Structures of bupropion and its photoactive probe.  
 
 
 
 
 
  
  
 
 
103 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.4. Two-dimensional docking interaction plot of the bupropion photoprobe. 
The hydrophobic residues (green spheres) and hydrophilic residues (pink spheres) in the 
pocket are displayed. The azide group (N3) interacts with Asp 475 demonstrating the 
possibility of covalent bond formation with the residue. 
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Figure 3.5.  PLIF panel of bupropion and photoprobe docked poses. Each docked 
pose is indicated by a row, black rectangles in each row represent the interacting residues.  
A residue may interact with a docked pose in six different ways, with more than one 
rectangle observed for a single residue. The red bracket represents bupropion poses and 
the blue bracket indicates the photoprobe docked poses. The panel clearly shows the 
increased interaction profile of photoprobe with Asp 475.  
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Pyrovalerone: The differences between the bupropion and pyrovalerone were very 
minimal with a great difference in affinity. Bupropion consists a secondary nitrogen, 
where as the pyrovalerone contains a tertiary nitrogen. The other minor difference was the 
pyrovalerone had a longer alkyl chain (n-propyl group) compared to the shorter methyl 
chain in bupropion. The larger pyrovalerone is fifty fold stronger than bupropion in DAT. 
Substitution on the aromatic ring of pyrovalerone was also better tolerated as in 
bupropion without any appreciable loss of affinity (Figure 3.6). The pyrovalerone 
photoprobe was designed by substituting the 4’-methyl group with photoreactive azide (-
N3) and iodine (I) at the 3’ position. The bulky substitutions on the final photoprobe result 
in ten-fold less affinity compared to pyrovalerone.  
 
 
 
 
 
Aromatic 
substituent 
R1 (3’)    R2 (4’) 
Compound 3H-WIN binding inhibition 
Ki  (nM) 
H Me Pyrovalerone 8 ± 2 
I N3 Photoprobe 78 ± 18 
H NH2 Amino pyrovalerone 5 ± 1 
I NH2 Amino, iodo-pyrovalerone 28 ± 8 
 
Figure 3.6. DAT binding affinity of pyrovalerone and its analogues. (Provided by Dr. 
David J. Lapinsky) 
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The five-fold affinity difference between the amino substituted pyrovalerone and 
the dual substituted pyrovalerone suggest the detrimental effect of bulky iodine group. 
Similar to the bupropion photoprobe, the pyrovalerone photoprobe also showed an 
increased interaction pattern with Asp 475. As the scaffolds of bupropion and 
pyrovalerone were similar, the ionic interaction with Asp 475 is no strange observation. It 
is proposed that the photoprobes based on these scaffolds would form a covalent bond 
with the charged residue.  
 
Methylphenidate: It is structurally larger and diverse compared to bupropion and 
pyrovalerone. The iodo and azido-substitution on the same ring motif, may lead to a low 
efficient photoprobe for this scaffold, and so methylphenidate was hybridized to better 
accommodate the iodo and azido groups on separate rings without a loss in affinity 
(Figure 3.7). The fingerprint analysis of methylphenidate showed no H-bonding pattern 
due to the lack of H-bond groups.  The PLIF analysis identified that the methylphenidate 
and iodo-substituted analogs interact with Thr 472 and Asp 475 residues. 
 Much like the other two scaffolds, the halogen substitution on the aromatic ring 
was well tolerated on this scaffold. The para-azido substitution on the hybrid analogues 
had better affinity compared to the ortho and meta-substituted analogs. The azido group 
substituted on the hybrid analogues formed a H-bond with Ser 308 (TM6) and an ionic 
interaction with Asp 312 (TM6).  Based on the PLIF pattern identified, it is speculated that 
the nitrene generated will covalently link to either one of these residues. 
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Substitution Compound 3H-WIN binding inhibition 
Ki  (nM) 
H Methylphenidate 25 ± 1 
4-I 4-I-methylphenidate 14 ± 3 
3-I 3-I-methylphenidate 4.5 ± 1 
p-N3-4-I p-N3-N-Bn-4-I-methylphenidate 363 ± 28 
m-N3-4-I m-N3-N-Bn-4-I-
methylphenidate 
2754 ± 169 
o-N3-4-I o-N3-N-Bn-4-I-methylphenidate 517 ± 65 
p-N3-3-I p-N3-N-Bn-3-I-methylphenidate 658 ± 70 
m-N3-3-I m-N3-N-Bn-3-I-
methylphenidate 
2056 ± 73 
o-N3-3-I o-N3-N-Bn-3-I-methylphenidate 1112 ± 163 
 
Figure 3.7. Structures and activity profile of methylphenidate analogues. (Provided by 
Dr. David J. Lapinsky) 
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3.4 Conclusion 
Numerous DAT photoaffinity probes with diverse scaffolds were developed for 
identifying the inhibitor-binding pocket in DAT. They include tropane-based and 
piperazine-based analogues with a very long flexible linker, separating the azide group 
and the pharmacophore. These scaffolds have an inherent problem with the covalent bond 
forming far from the binding pocket. This defeats the purpose of the scaffolds, and so the 
search for probes with the photoactive groups directly on the scaffold or with a short tether 
would help in better identification of the binding pocket of DAT inhibitors.  
The PLIF analysis of bupropion photoprobe showed the increased possibility of 
covalent bond formation with the Asp 475. It was noticed that the pyrovalerone 
photoprobe also showed a similar interaction pattern as the bupropion photoprobe. This is 
no strange observation being the two scaffolds were very similar. The methylphenidate 
and its hybrid analogs were bigger compared to the probes of other scaffolds and so a 
difference in interaction pattern was observed.  It was identified that Ser 308 and Asp 312 
residues were closer to the azido group, and the methylphenidate probe may form a 
covalent bond with either one of these residues. 
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Chapter 4. 
RATIONAL DESIGN OF NOVEL ORTHO-AMIDO 
DIPHENYLAMINES AS SELECTIVE MEK5 INHIBITORS 
THROUGH DEVELOPMENT OF A MEK5 HOMOLOGY 
MODEL 
 
4.1 Introduction 
Kinases are important cellular proteins that catalyze the transfer of a terminal 
phosphoryl group from adenosine triphosphate (ATP) to specific hydroxyl groups of 
serine, threonine or tyrosine residues.
1
  Mutations of these residues to acidic counterparts 
(often called DD, EE, or DE mutants) render kinases with significantly elevated activity, 
commonly observed in several cancers.  Mitogen activated protein kinase [(MAPKs), also 
called as extracellular signal regulated kinases (ERKs)] belong to the family of Ser/Thr 
kinases.  The MAPK pathway consists of a series of numerous interconnected signal 
transduction pathways that transfer extracellular responses into the cell nucleus, to control 
several cellular responses such as embryogenesis, proliferation and cell death (Figure 
4.1).
2-7
 
The human genome encodes seven MEK enzymes that regulate the activity of 
MAP kinase pathways.  Aside from the highly similar MEK1/MEK2, other members of 
the family consist of MEK3, MEK4, MEK5, MEK6 and MEK7.  Of all these proteins, 
MEK5 present as an attractive target for therapeutic intervention, because of the detection 
of elevated levels in squamous cell carcinoma
8
, prostrate
9
 and breast cancers.
10
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Drug resistance to the approved anticancer agents like imatinib, gefitinib and 
erlotinib has become a growing concern.
11
  To address this, another interesting concept is 
in the developmental stages, where inhibitors with more specificity and minimal side 
effects are being developed. The inhibitors attack the targets downstream ensuring that 
only certain functions are eliminated in the signaling cascade.  These inhibitors are called 
non-classical kinase inhibitors, where they occupy a pocket allosteric to the substrate ATP 
pocket, there by becoming effective against only a selected panel of kinases.
12
 Two studies 
of MEK5 inhibitors were reported. One study involves the development of oxindole 
derivatives
13
 as classical kinase inhibitors (ATP-competitive); where as the other study
14
 
reported the development of non-classical (allosteric) inhibitors.  It is assumed that the 
allosteric inhibitor binding induces a conformational change in the unphosphorylated 
kinase (MEK) by locking it into a catalytically inactive conformation.
3
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Figure 4.1. The signaling cascade of MEK family.
14
 (Adapted with permission from 
Flaherty et al. BMCL 2010,20, 2892-2896.) 
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4.2 Methods 
4.2.1 Retrieval of sequence  
Three different isoforms- A, B and C of human MEK5 were identified (Figure 
4.2).
15-17
  The splice variant B (referred to as MEK5 β further) is the canonical sequence; 
and longer (448 residues) than the remaining isoforms, expressed primarily in cytosol. The 
isoforms, “A” and “C” were comparatively shorter, with isoform A being the shortest. The 
fasta sequence of human MEK5 β (accession number Q13163) was downloaded from the 
Uniprot database
18.  MEK5 β has a conserved motif “S311xxxT315” which is the 
phosphorylation, and activation motif.  Mutagenesis of Ser 311 and Thr 315 to Asp 
residue constitutively activates MEK5, whose levels are observed to be significantly 
elevated in different types of cancer.  By mutating these two residues to aspartate in the 
downloaded primary sequence a constitutively active mutant was generated (Figure 
4.3).
16
  
 
 
 
 
 
 
 
 
 
  
 
 
118 
 
 
 
 
ISOFORM B 
>sp|Q13163|MP2K5_HUMAN Dual specificity mitogen-activated protein kinase kinase 5 
OS=Homo sapiens GN=MAP2K5 PE=1 SV=2 
MLWLALGPFPAMENQVLVIRIKIPNSGAVDWTVHSGPQLLFRDVLDVIGQVLPEA
TTTAFEYEDEDGDRITVRSDEEMKAMLSYYYSTVMEQQVNGQLIEPLQIFPRACK
PPGERNIHGLKVNTRAGPSQHSSPAVSDSLPSNSLKKSSAELKKILANGQMNEQDI
RYRDTLGHGNGGTVYKAYHVPSGKILAVKVILLDITLELQKQIMSELEILYKCDSS
YIIGFYGAFFVENRISICTEFMDGGSLDVYRKMPEHVLGRIAVAVVKGLTYLWSL
KILHRDVKPSNMLVNTRGQVKLCDFGVSTQLVNSIAKTYVGTNAYMAPERISGE
QYGIHSDVWSLGISFMELALGRFPYPQIQKNQGSLMPLQLLQCIVDEDSPVLPVG
EFSEPFVHFITQCMRKQPKERPAPEELMGHPFIVQFNDGNAAVVSMWVCRALEER
RSQQGPP------ 
 
 
Figure 4.2. Multiple sequence alignment of different isoforms of human MEK5. 
Consensus of residues among the three isoforms displayed, stars represent identical 
residues, dots represent dissimilar residues, and gaps shown by dashes. 
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Isoform B (wild type)  
MLWLALGPFPAMENQVLVIRIKIPNSGAVDWTVHSGPQLLFRDVLDVIGQVLPEA
TTTAFEYEDEDGDRITVRSDEEMKAMLSYYYSTVMEQQVNGQLIEPLQIFPRACK
PPGERNIHGLKVNTRAGPSQHSSPAVSDSLPSNSLKKSSAELKKILANGQMNEQDI
RYRDTLGHGNGGTVYKAYHVPSGKILAVKVILLDITLELQKQIMSELEILYKCDSS
YIIGFYGAFFVENRISICTEFMDGGSLDVYRKMPEHVLGRIAVAVVKGLTYLWSL
KILHRDVKPSNMLVNTRGQVKLCDFGVSTQLVNSIAKTYVGTNAYMAPERISGE
QYGIHSDVWSLGISFMELALGRFPYPQIQKNQGSLMPLQLLQCIVDEDSPVLPVGE
FSEPFVHFITQCMRKQPKERPAPEELMGHPFIVQFNDGNAAVVSMWVCRALEERR
SQQGPP 
Isoform B DD (constitutively active mutant) 
MLWLALGPFPAMENQVLVIRIKIPNSGAVDWTVHSGPQLLFRDVLDVIGQVLPEA
TTTAFEYEDEDGDRITVRSDEEMKAMLSYYYSTVMEQQVNGQLIEPLQIFPRACK
PPGERNIHGLKVNTRAGPSQHSSPAVSDSLPSNSLKKSSAELKKILANGQMNEQDI
RYRDTLGHGNGGTVYKAYHVPSGKILAVKVILLDITLELQKQIMSELEILYKCDSS
YIIGFYGAFFVENRISICTEFMDGGSLDVYRKMPEHVLGRIAVAVVKGLTYLWSL
KILHRDVKPSNMLVNTRGQVKLCDFGVSTQLVNDIAKDYVGTNAYMAPERISG
EQYGIHSDVWSLGISFMELALGRFPYPQIQKNQGSLMPLQLLQCIVDEDSPVLPVG
EFSEPFVHFITQCMRKQPKERPAPEELMGHPFIVQFNDGNAAVVSMWVCRALEER
RSQQGPP 
 
Figure 4.3. Differences between the wild type MEK5 isoform β and its constitutively 
active mutant. The dissimilarities are indicated with pink colored residues. 
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4.2.2 Search for the template  
Seven members have been identified that belong to the MEK family.
14
  The 
phylogenetic analysis reveals that MEK5 is more closely related to MEK1 with 48% 
sequence identity (Figure 4.4). A search for the MEK1 crystal structures identified 14 
different crystal structures in PDB (accessed Dec 2010).
19
   The protein with pdb id (3eqc) 
was selected as the template and the coordinates were downloaded and loaded into 
Discovery studio 2.5.1. (DS)
20
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Figure 4.4. Phylogenetic analysis of the members of MEK family. MEK1, MEK2 and 
MEK5 belong to a group, where as the rest of the family members are more evolutionarily 
related to each other.  
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4.2.3 Protein check of the template  
The template was checked for missing residues/atoms (protein quality) using 
protein reports and utilities module in DS.  The report identified missing residues at both 
the polypeptide terminals, gaps between residues Ala 220 and Val 224, gaps between Cys 
277 and Pro 307 in the template.  As the missing residues at both the terminals and the 
residues between Cys 277 and Pro 307 in the alpha helix domain were far from the 
binding pocket, no effort was taken to build the 3D coordinates.  The residues between 
Ala 220 and Val 224 in the activation loop were built and refined by the loop refinement 
protocol in DS.  Of the five residues modeled, only Phe 223 had two different plausible 
conformations generated (Figure 4.5).  The conformation pointing into the allosteric 
pocket is labeled as Phe 223_in and the one pointing towards p-loop is labeled as Phe 
223_out.  
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Figure 4.5. The two different conformations of Phe 223 generated in MEK1 through 
loop modeling. The amino acid residue is displayed as ball and sticks. The conformation 
pointing into the allosteric pocket is labeled as Phe 223_in (orange) and the conformation 
pointing up towards p-loop is labeled as Phe 223_out (green). 
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4.2.4 Sequence Alignment 
Using default settings on the clustalW2 server,
21
 the amino acid sequences of 
active mutant MEK5 βDD and modified 3eqc were aligned (Figure 4.6).  The two 
important motifs DFG and HRD were made sure to align between the sequence and 
template.  
 
 
 
 
 
 
 
 
 
Figure 4.6. Sequence alignment of MEK5 β DD and MEK1 used to build homology 
models. Conserved residues between MEK1 (top) and MEK5 β DD (bottom) are 
highlighted in yellow; similar residues highlighted in red. Secondary structure elements 
are displayed on top of the sequences with helices as coils, beta-strands as blue arrows and 
loops as black lines. Gaps relative to the other sequence are shown as dots. Residues are 
numbered and indicated at the beginning and end of each line. Stars at the bottom identify 
the phosphorylation residues: Ser 311 and Thr 315 mutated to Asp and black boxes 
highlight the conserved domains HRD and DFG. 
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4.2.5 MEK5 model construction 
The two different templates that varied in the Phe 223 conformation were used to 
construct homology models. The model building resulted in the generation of two 
different MEK5 β DD models, which differed in the orientation of Tyr 316, an analogous 
residue to Phe 223 in MEK1.  Both the templates were used to construct homology 
models, as there was no knowledge of the preferred conformation among the MEK family 
and with the loop being very flexible. Ten models of MEK5 β DD were built using each 
template resulting in the creation of a total of twenty models.  A model was picked from 
each set based on the discrete optimized protein score
22
 (DOPE) and 3D profile scores for 
further docking calculations.  
 
4.2.6 Docking 
Various diphenyl amino analogues tested at MEK1 and MEK5 were used to 
comprehend the interaction pattern of allosteric inhibitors with MEK5 (unreported). The 
coordinates of these ligands were drawn using builder in molecular operating 
environment
23
 (MOE) and partial charges, hydrogen atoms were added using Merck 
molecular force field 94X (MMFF94x).
24, 25
 The geometry of ligands was optimized using 
energy minimization module with a convergence criteria of 0.01 kcal/mol in MOE. The 
coordinates of Mg
+
 ion were copied from the template MEK1 to MEK5 models to mimic 
the natural cellular environment. Three independent docking runs of the diphenylamine 
analogues were performed at both the homology models of MEK5 β DD.  
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4.3 Results and Discussion 
4.3.1 Homology Modeling 
MEK5 belongs to the family of Ser/Thr kinases and so the phosphorylation motif 
residues, Ser 311 and Thr 315 present in the activation loop were both mutated to Asp, to 
mimic the constitutively active mutant MEK5 β DD.  The rotamers that mirrored the 
coordinates of Ser and Thr were selected; and keeping the rest of residues fixed, the new 
coordinates were energy minimized in MOE.  As MEK5 is more evolutionarily related to 
MEK1, the search for MEK1 in PDB resulted in identification of 14 X-ray structures.  
The pdb id (3eqc) was chosen as the crystal structure was obtained at a higher 
crystallographic resolution.  The protein report identified missing residues in the template 
with a gap between the residues Ala 220 and Val 224.  The missing residues Asn 221, Ser 
222 and Phe 223 present in the activation loop may play a significant role in the allosteric 
inhibition and ERK phosphorylation, as they were closer to the allosteric pocket.  The 
other reason to construct the 3D coordinates is the uncertainty in the different 
conformations adopted by Phe 223 revealed by fourteen different MEK crystal structures 
(Figure 4.7). 
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Figure 4.7. Superposition of the fourteen MEK1 crystal structures. The protein, 
MEK1 is displayed as wires with ATP displayed as sticks (atom type color), allosteric 
inhibitor is exhibited as ball and sticks (atom type color) and Mg
+2
 ion as brown sphere.  
Different conformations adopted by Phe 223 residue present in the activation loop show 
the substantial loop movement.  
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The ambiguity in the Phe 223 conformation and missing residues next to the 
allosteric pocket in the template led the effort to construct the 3D coordinates.  The 
coordinates of these residues were built using the loop refinement protocol available in 
DS.  Of the three residues modeled, the protocol generated two possible different 
conformations with equal probability for Phe 223, and a single optimal conformation for 
rest of the residues.  
The templates with different conformations of Phe 223 were selected based on a 
low DOPE score.  DOPE is an atomistic based statistical potential for the model 
evaluation and structure prediction.  This score is viewed as a conformational energy that 
measures the relative stability of one conformation with respect to others.  Therefore, the 
two templates with different rotamers of Phe 223 were used to construct the models of 
MEK5 β DD.  
By aligning the conserved motifs (HRD and DFG) followed by nonconserved 
domains between MEK1 and MEK5, a sequence alignment was generated.  Even though 
the overall sequence identity (~40%) is less, there is a higher homology (~80%) in the 
binding pockets.  The sequence alignment identified Tyr 316, to be an analogous residue 
to Phe 223 present in the activation loop (Figure 4.7).  Even though both residues were 
aromatic, Tyr 316 may form additional H-bond and cation-π interactions with allosteric 
inhibitors. 
Using the sequence alignment and two MEK1 templates, ten models of MEK5 
active mutant were constructed for each template. So a total of ten MEK5 models with Tyr 
316 pointing into the allosteric pocket and ten models with Tyr 316 pointing up towards 
the p-loop were generated.  Two models with favorable DOPE scores were selected from 
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each group.  The Ramachandran plots (Figure 4.8) of these two models in both the groups 
were analyzed to pick a final model with a least number of outliers, resulting in two final 
MEK5 models with different conformations of Tyr 316.The all-atom force field, assisted 
model building with energy refinement (AMBER 99) was used to add partial charges and 
hydrogen atoms to MEK5 homology models.
26, 27
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Figure 4.8. Sequence alignment of activation loop of MEK1 (top) and MEK5 β DD 
(bottom). Identical residues are highlighted by yellow and similar residues by red. Black 
boxes represent the conserved motifs. The analogous residue to Phe 223 (MEK1) is Tyr 
316 (MEK5) is represented by a blue sphere at the bottom. 
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Figure 4.9. Ramachandran plot of the final MEK5 β DD homology model. The 
outliers in the model that are away from the binding pockets are represented by plus signs 
with non-outliers as green and yellow spheres. 
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4.3.2 Docking 
A series of diphenylamines with amine side chain modification were synthesized 
previously, and tested for inhibition of relative phosphorylation at ERK1/2 and ERK5 
(unreported) (Table 4.1).  The ability of diphenylamine analogues to block in vivo EGF-
induced ERK1/2 and EKR5 phosphorylation was measured using this assay. This assay is 
purely a qualitative measurement of inhibition of relative phosphorylation of ERK5 
induced by mutagens 
The 3D structures of diphenylamine analogues were built and refined using MOE. 
The homology models of MEK5 β DD were then loaded in MOE. The magnesium ion 
present in the MEK1 crystal structure was added to both MEK5 final models to mimic the 
natural cellular environment. As there is a higher homology in the allosteric pockets 
between MEK1 and MEK5; and PD0325901 being a diphenylamine analogue, a 
reasonable assumption was made that the newly designed analogues will also bind in a 
similar fashion to MEK5.  So the co-crystallized MEK1inhibitor, PD0325901 was also 
added to both the models to guide the docking studies.  As the activation and p-loops were 
very flexible, both models of MEK5 β DD were used further to dock diphenylamine 
analogues. 
Three independent docking runs were performed keeping the side chains of pocket 
residues in 6Å relaxed and backbone atoms fixed.  As the allosteric pocket is bound and 
formed by mostly flexible loops, docking was modeled by allowing the side chain 
flexibility.  Of the seven analogues docked, iodine atom on the ligand with the shortest 
side chain was found to interact electrostatically with the backbone carbonyl of Ile 225. 
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The amide side chain was observed to from H-bond with Lys 195, Asp 301 and with 
hydroxyl group of Tyr 316 (Figure 4.9).  
The piperazine, morpholine and piperidine analogues oriented in a similar fashion 
with heterocyclic rings forming hydrophobic stacking with Tyr 316.  The rest of the 
analogues with beta-hydroxyl side chain, and amino acid substitutions were observed to 
form favorable interactions in the pocket.  Even though the last three analogues were 
computationally favorable, no inhibition of relative phosphorylation was observed 
experimentally at both ERK1/2 and ERK 5.  The reason may be due to the pocket being 
hydrophobic and the analogues being hydrophilic. Careful visual inspection of all the 
docked poses of analogues and scores showed that Tyr 316_in conformation was favored 
over the Tyr 316_out conformation. Therefore the MEK5 homology model with Tyr 
316_in conformation was chosen as the final model for further studies. 
 As the diphenylamine analogues were active at both MEK1 and MEK5, 
and some compounds showed selectivity towards MEK5 (Table 4.1), the structures of 
both proteins were superposed to identify the differences in the pockets (Figure 4.10).  
Using the interaction pattern identified by diphenylamine analogues and the structural 
differences between these two proteins, three different series of inhibitors were designed 
(Figure 4.11). The first series was to simulate the in vivo Mg ion, the Tyr 316 series was 
designed to interact with Tyr 316 residue in the activation loop and lock the protein in an 
inactive conformation, where as the central ring modifications were to find the minimal 
halogen substitution on rings.  
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Analogue  
(R) 
Amide  
variation 
pERK1/2 
relative % 
phosphorylation 
pERK5 
relative % 
phosphorylation 
-NH2 NH2 3.19 41.0 
 1-methyl 
piperazine 
254.0 63.0 
 morpholine 251.0 72.0 
 piperidine 233.0 82.0 
 β-hydroxy 
ethyl 
1.65 45.0 
 (S) serine 218.0 100.0 
 (R) serine 174.0 121.0 
blank  100.0 100.0 
 
Table 4.1. Various biphenyl analogues of PD0325901 synthesized and tested for 
inhibition of phosphorylation of the substrate. (Provided by Dr. Patrick T. Flaherty) 
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Figure 4.10. Docking interactions of the shortest side chain diphenylamine analogue 
with MEK5 β DD. Residues interacting with the ligand (sticks in atomtype color) 
displayed as lines (atomtype color) and MEK5 is represented as yellow cartoon. The 2D 
interaction plot shows the ligand interactions in the allosteric pocket.  
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Figure 4.11. Superposition of crystal structure of 3EQC (grey) over model of MEK5 
β DD (red). The allosteric ligand of 3EQC is shown as sticks. Residues differing in both 
the catalytic site as well as the allosteric pocket are highlighted and colored according to 
the protein chain. 
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  Mg ion mimetics                     Tyr 316 series        Central ring modification 
                                               
         
 
 
 
 
 
 
 
 
 
 
Figure 4.12. Different series of MEK5 inhibitors designed. Mg mimetic is to simulate 
the Mg ion role, Tyr 316 series is supposed to interact and lock Tyr 316 residue present in 
the activation loop; central ring modifications are to identify minimal substitution on the 
ring without substantial loss of activity. 
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4.4 Conclusion 
MEK5 is significantly upregulated in breast and prostate cancers.  A series of ATP 
competitive ligands were developed for kinases, but the mutational strategy played by the 
cancer downplays these inhibitors.  Moreover, ATP competitive ligands were not selective 
and had failed before reaching preclinical trials.  The new focus of developing small 
molecules for kinases is through allosteric inhibitors thereby stopping the signaling 
cascade necessary for cancer cell survival.  In this study, a homology model of MEK5 β 
DD was developed and refined. The model was utilized to guide the rational design of 
allosteric inhibitors through docking and different series of analogues were proposed to 
inhibit ERK5 phosphorylation. 
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Conclusions and Future Directions 
 Based on the results presented in this dissertation, several new research objectives 
are recommended. 
The usage of antidepressants in the market is limited by their side effects. New 
antidepressants with reduced side activity profile are sought. Among the newer generation 
is the recently approved antidepressant “Vilazodone”. It is a dual acting antidepressant 
with SERT inhibitory action, and partial agonistic activity at the 5-HT1A receptor.  The 
physiological role of 5-HT1A receptor is to inhibit feedback mechanism that decreases 
serotonin concentration in the synapse. The blockade of 5-HT1A receptor in addition to 
SERT results in rapid onset of antidepressant action with less side effect profile. 
From a SERT perspective, two selective novel scaffolds (SM-10, SM-11) were 
identified form virtual screening. Additionally, a DAT selective compound (SM-14) was 
identified, which could be developed towards treating cocaine addiction. The two SERT 
selective compounds can serve as promising drug candidates for further drug 
development, and rational optimization of these two hits could be performed. The 
substitution of non-halogenated heterocyclic rings with serotonin-like indole moiety could 
be performed to increase the SERT affinity. Like vilazodone, the two SERT-selective hits 
could also be rationally optimized as multi-site drugs.  
More specifically, SM-10 having the lowest affinity towards SERT has three 
stereo centers present. The isolation and affinity measurement of different enantiomers of 
SM-10 could also be performed to identify the higher affinity analogue. Moreover, 
different combinations of halogen substitution on the phenyl ring could also be identified 
for optimal SERT inhibition. 
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 Computationally, the hits identified showed an array of interactions with residues 
in the S2 pocket. Mutagenesis studies on these residues could be carried out in an effort to 
confirm that these ligands are indeed binding in the S2 pocket as predicted. Specifically, 
the residues Arg104 (TM1), Tyr107 (TM1), Lys490 (TM10), and Glu493 (TM10) could 
be mutated to alanine to disrupt the H-bonding potential. Likewise, the halogen binding 
pocket residues Leu 99 (TM1), Trp103 (TM1) and Ile179 (TM3) could also be mutated to 
ascertain the importance of this pocket.  
 Inhibitor binding pocket identification in MATs is a challenging task. The DAT 
study developed and analyzed protein-ligand interaction fingerprints (PLIF) for three 
structurally different photoprobes. Preliminary results suggest the role of Ser308, Asp312 
and Asp475 residues forming a covalent bond with the photoprobes. Mutational studies of 
these residues could be performed to ascertain the location of covalent bond formation. 
Additionally, mass spectrometry studies could be performed to better corroborate with the 
PLIF and mutational data.  
The MEK5 kinase study led to the rational design of several series of inhibitors. 
The MEK5 inhibitory cellular assay could be performed on the inhibitors to better 
understand the mechanics of inhibition. Moreover, the biological results could help in the 
validation and refinement of the MEK5 homology model. The biological activity of the 
central ring modification series could provide minimal substitution required for MEK5 
inhibition. In addition, this series will help in improving the solubility of these analogs by 
eliminating the hydrophobic halogen groups on the rings.  
 
 
